id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1205504133182169091,1205504133182169091,2019-12-13 20:35:57 IST,2019-12-13,20:35:57,+0530,2926103221,boskovic64,Joe Boskovich,,"I think it‚Äôs definitely worth the 15 minutes to check out Rafael Holdings new slide deck. Very interesting asset + very interesting new initiative, #BarerInstitute, named after Celgene Founder and CEO, Sol Barer, $RFL $CELG #howardjonasspinoff",en,[],[],[],0,1,9,"['barerinstitute', 'howardjonasspinoff']","['rfl', 'celg']",https://twitter.com/boskovic64/status/1205504133182169091,False,https://twitter.com/SeekingAlpha/status/1205176403752153088,0,,,,,,,,[],,,,
1203864358461177858,1203864358461177858,2019-12-09 08:00:04 IST,2019-12-09,08:00:04,+0530,950942636818432006,syinvesting,SY Investing,,"$BMYRT (Bristol-Celgene CVR) should be notably up tomorrow. $BMY $CELG  Two positive updates this weekend: 1) ""Approvable"" $BLUE bb2121 r/r MM data 2) Good JCAR017 data &amp; indication of *YE'19 BLA filing*  Cautious perspectives from @Vantageanalysis below   https://t.co/tXpzaCdiYq",en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['https://www.evaluate.com/vantage/articles/events/conferences/ash-2019-former-celgene-holders-look-anxiously-contingent-value'],[],1,3,15,[],"['bmyrt', 'bmy', 'celg', 'blue']",https://twitter.com/syinvesting/status/1203864358461177858,False,,0,,,,,,,,[],,,,
1197266151018909696,1195542439462727680,2019-11-21 03:01:09 IST,2019-11-21,03:01:09,+0530,950942636818432006,syinvesting,SY Investing,,$BMY completes acquisition of $CELG. The deal was first announced on 01/03/19.  Bristol CVRs to trade as $BMYRT (starting 11/21/19). Celgene CVRs to trade as $CELGRT (starting 12/02/19).  Bristol also announced the repurchase of $7B of common stock.   https://t.co/dJoLAH4fmK,en,[],['https://www.businesswire.com/news/home/20191120005929/en/Bristol-Myers-Squibb-Completes-Acquisition-Celgene-Creating-Leading'],[],2,2,6,[],"['bmy', 'celg', 'bmyrt', 'celgrt']",https://twitter.com/syinvesting/status/1197266151018909696,False,,0,,,,,,,,[],,,,
1197264417039278081,1197264417039278081,2019-11-21 02:54:15 IST,2019-11-21,02:54:15,+0530,3043828834,cgrantwsj,Charley Grant,,Bristol-Myers Celgene CVR is about to start trading on NYSE now that deal has closed. Here is my primer from September $BMY $CELG  https://t.co/1zpkyCc68p,en,[],['https://www.wsj.com/articles/a-big-biotech-bet-hiding-in-plain-sight-11569321001'],[],1,6,23,[],"['bmy', 'celg']",https://twitter.com/CGrantWSJ/status/1197264417039278081,False,,0,,,,,,,,[],,,,
1197263624873676800,1197263624873676800,2019-11-21 02:51:06 IST,2019-11-21,02:51:06,+0530,19717430,zbiotech,zach,,"$CELG $BMY $CELGRT  The Celgene CVRs are expected to begin trading on the NYSE under the symbol ""CELGRT"" following their official delisting from the NASDAQ Global Market, which is expected to occur on December 2, 2019",en,[],[],[],3,0,11,[],"['celg', 'bmy', 'celgrt']",https://twitter.com/zbiotech/status/1197263624873676800,False,,0,,,,,,,,[],,,,
1196514076400214018,1196514076400214018,2019-11-19 01:12:40 IST,2019-11-19,01:12:40,+0530,991763034304598016,chopraftc,Rohit Chopra,,"From 1995-2015, 60 pharma companies morphed into just 10 giants. The FTC almost never sues to block these deals, and the agency just approved an agreement with @BMSNews &amp; @Celgene that will lead to another massive merger. Here's why I voted no. $BMY $CELG  https://t.co/IvEQxfbivA",en,"[{'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",['https://www.ftc.gov/public-statements/2019/11/dissenting-statement-commissioner-rohit-chopra-matter-bristol-myers-squibb'],[],2,29,49,[],"['bmy', 'celg']",https://twitter.com/chopraftc/status/1196514076400214018,False,,0,,,,,,,,[],,,,
1195710129913651200,1195710129913651200,2019-11-16 19:58:04 IST,2019-11-16,19:58:04,+0530,102754598,johncendpts,John Carroll,,"I started out doing something for the record, but I ended up writing a story with major implications for the industry in 2020 -- FTC clears Bristol-Myers‚Äô $74B deal to buy Celgene ‚Äî but Dems signal a potential hard shift against Big Pharma M&amp;A $BMY $CELG  https://t.co/NCF2c1hKyG",en,[],['https://endpts.com/ftc-clears-bristol-myers-74b-deal-to-buy-celgene-but-dems-signal-a-potential-hard-shift-against-big-pharma-ma/'],[],0,1,8,[],"['bmy', 'celg']",https://twitter.com/JohnCendpts/status/1195710129913651200,False,,0,,,,,,,,[],,,,
1195709862619074561,1195709862619074561,2019-11-16 19:57:01 IST,2019-11-16,19:57:01,+0530,3460109487,endpts,Endpoints News,,"NEW ‚Äî FTC clears Bristol-Myers‚Äô $74B deal to buy Celgene, but Dems signal a potential hard shift against Big Pharma M&amp;A   https://t.co/EDbKzdkxra $CELG $BMS",en,[],['https://endpts.com/ftc-clears-bristol-myers-74b-deal-to-buy-celgene-but-dems-signal-a-potential-hard-shift-against-big-pharma-ma/'],[],0,2,5,[],"['celg', 'bms']",https://twitter.com/endpts/status/1195709862619074561,False,,0,,,,,,,,[],,,,
1192080498992074753,1192080498992074753,2019-11-06 19:35:13 IST,2019-11-06,19:35:13,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"#ASH19 preview: Celgene, Bluebird, and J&amp;J out with early but telling data in blood cancer  https://t.co/GdkRjSgtAF $CELG $BMY $BLUE $JNJ I had embargoed access to abstracts, including liso-cel TRANSCEND NHL study results. Check it out.",en,[],['https://www.statnews.com/2019/11/06/ash-preview-celgene-bluebird-jnj-blood-cancer/'],[],2,18,44,['ash19'],"['celg', 'bmy', 'blue', 'jnj']",https://twitter.com/adamfeuerstein/status/1192080498992074753,False,,0,,,,,,,,[],,,,
1173913746172973057,1173913746172973057,2019-09-17 16:27:02 IST,2019-09-17,16:27:02,+0530,203652149,sjosephburns,Steve Burns,,"Best Performing S&amp;P 500 stocks, last 20 yrs...  Monster Beverage $MNST: +72,340% Tractor Supply $TSCO: +33,500% Cognizant Tech $CTSH: +14,150% HollyFrontier $HFC: +10,560% Ventas $VTR: +9,520% Apple $AAPL: +9,260% NVIDIA $NVDA: +9,140% Celgene $CELG: +8,880%  - @charliebilello",en,"[{'screen_name': 'charliebilello', 'name': 'charlie bilello', 'id': '1413027896'}]",[],[],5,76,212,[],"['mnst', 'tsco', 'ctsh', 'hfc', 'vtr', 'aapl', 'nvda', 'celg']",https://twitter.com/SJosephBurns/status/1173913746172973057,False,,0,,,,,,,,[],,,,
1173613990972444672,1172904208942739456,2019-09-16 20:35:54 IST,2019-09-16,20:35:54,+0530,1413027896,charliebilello,Charlie Bilello,,"Best Performing S&amp;P 500 stocks, last 20 yrs... Monster Beverage $MNST: +72,340% Tractor Supply $TSCO: +33,500% Cognizant Tech $CTSH: +14,150% HollyFrontier $HFC: +10,560% Ventas $VTR: +9,520% Apple $AAPL: +9,260% NVIDIA $NVDA: +9,140% Celgene $CELG: +8,880% Ansys $ANSS: +8,830%",en,[],[],[],6,46,176,[],"['mnst', 'tsco', 'ctsh', 'hfc', 'vtr', 'aapl', 'nvda', 'celg', 'anss']",https://twitter.com/charliebilello/status/1173613990972444672,False,,0,,,,,,,,[],,,,
1172178057064603650,1172178057064603650,2019-09-12 21:30:01 IST,2019-09-12,21:30:01,+0530,20119344,greenbackd,Tobias Carlisle,,George Soros's 6-30-2019 portfolio (value $4.3bb)  Top 10 Holdings  1 $LBRDK / Liberty Broadband $757mm 2 $VICI / Vici Properties   $453mm 3 $CZR / Caesars Entertainment $225mm 4 $QQQ $218mm 5 $AABA / Altaba $171mm 6 $RHT / Red Hat $97mm 7 $CELG / Celgene Corp $76mm 8 ...,und,[],[],[],1,6,18,[],"['lbrdk', 'vici', 'czr', 'qqq', 'aaba', 'rht', 'celg']",https://twitter.com/Greenbackd/status/1172178057064603650,False,https://twitter.com/acquirersx/status/1172085483989557249,0,,,,,,,,[],,,,
1166144670768017409,1166144670768017409,2019-08-27 05:55:30 IST,2019-08-27,05:55:30,+0530,993282182,pharris667,Harris Market Trends,,"IBD Big Picture August 26, 2019 Monday Action Indexes Bounce More than 1% Current Outlook Market Under Pressure Distribution Days 3 on Nasdaq 2 on S&amp;P Leaders Up in Volume $KEYS Keysight Tech $CELG Celgene $ULTA Ultra Beaty Leaders Down in Volume $SPLK Splunk  $ALXN Alexion",en,[],[],[],1,2,10,[],"['keys', 'celg', 'ulta', 'splk', 'alxn']",https://twitter.com/pharris667/status/1166144670768017409,False,,0,,,,,,,,[],,,,
1165944167329075201,1165944167329075201,2019-08-26 16:38:46 IST,2019-08-26,16:38:46,+0530,102754598,johncendpts,John Carroll,,BREAKING: Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene $AMGN $CELG $BMY  https://t.co/HXmDDWjsgx,en,[],['https://endpts.com/breaking-amgen-swoops-in-with-13-4b-deal-to-pluck-blockbuster-otezla-from-celgene/'],[],0,6,12,[],"['amgn', 'celg', 'bmy']",https://twitter.com/JohnCendpts/status/1165944167329075201,False,,0,,,,,,,,[],,,,
1156166434260733952,1156166434260733952,2019-07-30 17:05:33 IST,2019-07-30,17:05:33,+0530,3426014292,semodough,dough,,$CELG $BMY Celgene Reports Second Quarter 2019 Operating and Financial Results | Celgene Corporation  https://t.co/qrBQaVvgQV,en,[],['https://ir.celgene.com/press-releases/press-release-details/2019/Celgene-Reports-Second-Quarter-2019-Operating-and-Financial-Results/default.aspx'],[],2,5,8,[],"['celg', 'bmy']",https://twitter.com/semodough/status/1156166434260733952,False,,0,,,,,,,,[],,,,
1156165782876893184,1156165782876893184,2019-07-30 17:02:57 IST,2019-07-30,17:02:57,+0530,59393368,livesquawk,LiveSquawk,,Celgene 2Q Earnings: $CELG -Rev: $4.4B (est $4.24B) -Adj EPS: $2.86 (est $2.63) -Boosts 2019 Rev Forecast -Reaffirms 2020 Outlook,en,[],[],[],0,9,12,[],['celg'],https://twitter.com/LiveSquawk/status/1156165782876893184,False,,0,,,,,,,,[],,,,
1140468742452854784,1140466778625232896,2019-06-17 09:28:31 IST,2019-06-17,09:28:31,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,This is the link to $ZIOP latest webcast - non viral approaches. Threat #1 to $CELG $BMY oncology portfolio @Celgene @bmsnews  https://t.co/FFCygCU9Rc,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}]",['https://edge.media-server.com/m6/p/43uc5968'],[],0,2,4,[],"['ziop', 'celg', 'bmy']",https://twitter.com/Biotech2050/status/1140468742452854784,False,,0,,,,,,,,[],,,,
1122234442326654981,1122234442326654981,2019-04-28 01:51:55 IST,2019-04-28,01:51:55,+0530,3426014292,semodough,dough,,"BMO $CELG $BMY combined company will obviously be more diversified than Bristol or Celgene alone.forecast combined company will generate peak revenue of ~$50B in 2023, decline thereafter with loss of exclusivity impact of Revlimid (after 2022), Eliquis (2027), Opdivo (after 2028)  https://t.co/haQBIXWbnq",en,[],[],['https://pbs.twimg.com/media/D5L6RldWkAUfCwZ.jpg'],0,4,12,[],"['celg', 'bmy']",https://twitter.com/semodough/status/1122234442326654981,False,,1,https://pbs.twimg.com/media/D5L6RldWkAUfCwZ.jpg,,,,,,,[],,,,
1116981972620988416,1116981972620988416,2019-04-13 14:00:29 IST,2019-04-13,14:00:29,+0530,401575573,dividendc2,dividendc2,,"Mis TOP 5 - Mejores compa√±√≠as BIOTECHNOLOGY , largo plazo:  1: Amgen Inc (AMGN)  2: Gilead Sciences Inc (GILD)  3: Celgene Corp (CELG)  4: Illumina Inc (ILMN)  5: Vertex Pharmaceuticals Inc (VRTX)",ca,[],[],[],2,0,14,[],[],https://twitter.com/dividendc2/status/1116981972620988416,False,,0,,,,,,,,[],,,,
1116710136196866049,1116710136196866049,2019-04-12 20:00:18 IST,2019-04-12,20:00:18,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"The Bristol-Celgene merger is approved. Here are 8 challenges ahead  https://t.co/bmQtS471fV  $BMY $CELG (say goodbye to that ticker) By @damiangarde and yours truly. Plus, another great illustration from @HoganAlex",en,"[{'screen_name': 'damiangarde', 'name': 'damian garde', 'id': '529704495'}, {'screen_name': 'hoganalex', 'name': 'alex hogan', 'id': '296572811'}]",['https://www.statnews.com/2019/04/12/bristol-myers-squibb-celgene-challenges-ahead/'],[],4,7,17,[],"['bmy', 'celg']",https://twitter.com/adamfeuerstein/status/1116710136196866049,False,,0,,,,,,,,[],,,,
1116709492878606337,1116709492878606337,2019-04-12 19:57:45 IST,2019-04-12,19:57:45,+0530,15281391,thestreet,TheStreet,,BREAKING: Bristol-Myers $BMY shareholders vote to approve Celgene $CELG deal.,en,[],[],[],0,3,4,[],"['bmy', 'celg']",https://twitter.com/TheStreet/status/1116709492878606337,False,,0,,,,,,,,[],,,,
1116708681175924736,1116708342657949696,2019-04-12 19:54:31 IST,2019-04-12,19:54:31,+0530,19717430,zbiotech,zach,,*BMY: PRELIMINARY TALLY SHOWS 75% VOTE IN FAVOR OF CELGENE DEAL  $BMY $CELG,en,[],[],[],0,4,6,[],"['bmy', 'celg']",https://twitter.com/zbiotech/status/1116708681175924736,False,,0,,,,,,,,[],,,,
1116708342657949696,1116708342657949696,2019-04-12 19:53:10 IST,2019-04-12,19:53:10,+0530,19717430,zbiotech,zach,,*BRISTOL-MYERS WINS SHAREHOLDER VOTE ON CELGENE TAKEOVER  $BMY $CELG,en,[],[],[],3,12,35,[],"['bmy', 'celg']",https://twitter.com/zbiotech/status/1116708342657949696,False,,0,,,,,,,,[],,,,
1113506463085993984,1113506463085993984,2019-04-03 23:50:03 IST,2019-04-03,23:50:03,+0530,102754598,johncendpts,John Carroll,,"So for the record, I did ask representatives of Soon-Shiong and $CELG for a comment. Celgene's entire media group evidently went on a sabbatical about a year ago. Speaks volumes, doesn't it?  https://t.co/WwIDzmZSqG",en,[],['https://endpts.com/biotech-billionaire-faces-fresh-accusations-of-fraud-for-1-3b-catch-and-kill-cancer-drug-deal/'],[],0,8,26,[],['celg'],https://twitter.com/JohnCendpts/status/1113506463085993984,False,,0,,,,,,,,[],,,,
1111616513709142019,1111615675972374529,2019-03-29 18:40:04 IST,2019-03-29,18:40:04,+0530,19717430,zbiotech,zach,,*ISS RECOMMENDS BRISTOL-MYERS HOLDERS VOTE FOR CELGENE: CNBC  $BMY $CELG,en,[],[],[],1,1,7,[],"['bmy', 'celg']",https://twitter.com/zbiotech/status/1111616513709142019,False,,0,,,,,,,,[],,,,
1110999796863696896,1110999796863696896,2019-03-28 01:49:27 IST,2019-03-28,01:49:27,+0530,15568127,themotleyfool,The Motley Fool,,"So many great topics on today's @MFIndustryFocus show: Biogen's big pipeline blow up, the latest gene therapy M&amp;A news, and updates on the Bristol-Myers Squibb &amp; Celgene drama.  Subscribe wherever you get podcasts and Fool On! $BIIB $BMY $CELG $TMO  https://t.co/o8VtfPSle3",en,"[{'screen_name': 'mfindustryfocus', 'name': 'industry focus', 'id': '1548736957'}]",[],[],0,2,10,[],"['biib', 'bmy', 'celg', 'tmo']",https://twitter.com/themotleyfool/status/1110999796863696896,False,,1,https://pbs.twimg.com/ext_tw_video_thumb/1110999508685602819/pu/img/0auPrhFekyIaNXr2.jpg,,,,,,,[],,,,
1110538566633955331,1110538566633955331,2019-03-26 19:16:41 IST,2019-03-26,19:16:41,+0530,13171622,pharmalot,pharmalot,,"Pharmalot.. Pharmalittle.. Good Morning.. Purdue settles opioid lawsuit in Oklahoma, FTC asks Bristol &amp; Celgene for still more info... and more interesting news..  https://t.co/I4k3f4UlBl #pharma #opioids #drugprices $BMY $CELG $TEVA $JNJ $BAYRY $SRPT $CVS $MKKGY $VSM",en,[],['https://www.statnews.com/pharmalot/2019/03/26/purdue-opioid-lawsuits-bristol-celgene/'],[],0,2,5,"['pharma', 'opioids', 'drugprices']","['bmy', 'celg', 'teva', 'jnj', 'bayry', 'srpt', 'cvs', 'mkkgy', 'vsm']",https://twitter.com/pharmalot/status/1110538566633955331,False,,0,,,,,,,,[],,,,
1110491480043520001,1110491480043520001,2019-03-26 16:09:35 IST,2019-03-26,16:09:35,+0530,102754598,johncendpts,John Carroll,,"Buyout vote looming, Celgene files for ozanimod OK (again), with a multibillion-dollar bet riding on every step $CELG $BMY  https://t.co/G01MZ18DG2",en,[],['https://endpts.com/biotech-on-a-wire-celgene-files-for-ozanimod-ok-again-with-a-multibillion-dollar-bet-riding-on-every-step/'],[],2,3,4,[],"['celg', 'bmy']",https://twitter.com/JohnCendpts/status/1110491480043520001,False,,0,,,,,,,,[],,,,
1106162566135455744,1106162566135455744,2019-03-14 17:28:01 IST,2019-03-14,17:28:01,+0530,19717430,zbiotech,zach,,*CELGENE‚ÄôS REVLIMID PATENT ESCAPES IPR REVIEW SOUGHT BY ALVOGEN  $CELG $BMY,en,[],[],[],1,7,16,[],"['celg', 'bmy']",https://twitter.com/zbiotech/status/1106162566135455744,False,,0,,,,,,,,[],,,,
1105281666770259968,1105281666770259968,2019-03-12 07:07:39 IST,2019-03-12,07:07:39,+0530,3426014292,semodough,dough,,$CELG Celgene: The Phase I/II trial (NCT03331198) evaluating JCAR017 in subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) has moved ahead its primary completion date from August 2021 to December 2020.,en,[],[],[],0,2,7,[],['celg'],https://twitter.com/semodough/status/1105281666770259968,False,,0,,,,,,,,[],,,,
1105184443218710528,1105184443218710528,2019-03-12 00:41:19 IST,2019-03-12,00:41:19,+0530,1330055544,benthefidler,Ben Fidler,,"ICYMI earlier, very much appreciate all the positive feedback on this story, thank you!: The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski  https://t.co/aNnsIOtnH0 $CELG $NVS $AGIO $BLUE $XLRN $BMY",en,[],['https://xconomy.com/national/2019/03/11/the-life-troubles-and-celgene-legacy-of-deal-guru-george-golumbeski/'],[],1,0,7,[],"['celg', 'nvs', 'agio', 'blue', 'xlrn', 'bmy']",https://twitter.com/BentheFidler/status/1105184443218710528,False,,0,,,,,,,,[],,,,
1105063277338480641,1105063277338480641,2019-03-11 16:39:51 IST,2019-03-11,16:39:51,+0530,1330055544,benthefidler,Ben Fidler,,"The Life, Troubles, And Celgene Legacy of Deal Guru George Golumbeski  https://t.co/aNnsIOtnH0 $CELG $BMY $NVS $AGIO",en,[],['https://xconomy.com/national/2019/03/11/the-life-troubles-and-celgene-legacy-of-deal-guru-george-golumbeski/'],[],1,9,38,[],"['celg', 'bmy', 'nvs', 'agio']",https://twitter.com/BentheFidler/status/1105063277338480641,False,,0,,,,,,,,[],,,,
1103410298353057792,1103410298353057792,2019-03-07 03:11:30 IST,2019-03-07,03:11:30,+0530,102754598,johncendpts,John Carroll,,You think $BMY is running a tad scared? I heard back from their PR arm within minutes of running this: Another influential voice takes Bristol-Myers‚Äô top execs to task as they scramble to shore up the big Celgene buyout $BMY $CELG  https://t.co/heWlyhTAdt,en,[],['https://endpts.com/another-influential-voice-takes-bristol-myers-top-execs-to-task-as-they-scramble-to-shore-up-the-big-celgene-buyout/'],[],4,11,30,[],"['bmy', 'bmy', 'celg']",https://twitter.com/JohnCendpts/status/1103410298353057792,False,,0,,,,,,,,[],,,,
1103264340210266112,1103264340210266112,2019-03-06 17:31:31 IST,2019-03-06,17:31:31,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$BMY $CELG BRISTOL-MYERS SQUIBB SAYS ""CELGENE ACQUISITION HAS CLEAR STRATEGIC RATIONALE AND REPRESENTS A COMPELLING VALUE PROPOSITION""",en,[],[],[],2,1,12,[],"['bmy', 'celg']",https://twitter.com/_B_I_O_T_E_C_H_/status/1103264340210266112,False,,0,,,,,,,,[],,,,
1102655020833615872,1102655020833615872,2019-03-05 01:10:17 IST,2019-03-05,01:10:17,+0530,3426014292,semodough,dough,,$CELG $BLUE Celgene/Bluebird Bio: The Phase III trial (NCT03651128) evaluating bb2121 versus standard triplet regimens in subjects with Relapsed and Refractory Multiple Myeloma (RRMM) is now recruiting participants.,en,[],[],[],0,2,12,[],"['celg', 'blue']",https://twitter.com/semodough/status/1102655020833615872,False,,0,,,,,,,,[],,,,
1101194892146106368,1101194892146106368,2019-03-01 00:28:16 IST,2019-03-01,00:28:16,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?  https://t.co/LXN5a1pkK3 $CELG $BMY and another biotech ticker, but you need to read. h/t to @alissa_ambrose and @hoganalex for the wicked-cool illustration.",en,"[{'screen_name': 'alissa_ambrose', 'name': 'alissa ambrose', 'id': '198514721'}, {'screen_name': 'hoganalex', 'name': 'alex hogan', 'id': '296572811'}]",['https://www.statnews.com/2019/02/28/bristol-celgene-deal-shaky-celgene/'],[],5,3,16,[],"['celg', 'bmy']",https://twitter.com/adamfeuerstein/status/1101194892146106368,False,,0,,,,,,,,[],,,,
1100898211097645056,1100898211097645056,2019-02-28 04:49:21 IST,2019-02-28,04:49:21,+0530,102754598,johncendpts,John Carroll,,"Uh-oh Bristol-Myers‚Äô largest shareholder comes out against its $74B Celgene buyout, raising a ‚Äòreal risk‚Äô of torpedoing the deal $BMY $CELG  https://t.co/pjMPvFd5eO",en,[],['https://endpts.com/bristol-myers-largest-shareholder-comes-out-against-its-74b-celgene-buyout-raising-a-real-risk-of-torpedoing-the-deal/'],[],3,8,16,[],"['bmy', 'celg']",https://twitter.com/JohnCendpts/status/1100898211097645056,False,,0,,,,,,,,[],,,,
1100893202314395648,1100893202314395648,2019-02-28 04:29:27 IST,2019-02-28,04:29:27,+0530,292876633,kristen_hallam,Kristen Hallam,,BREAKING: Bristol-Myers' largest shareholder Wellington rejects $95B Celgene deal $BMY $CELG  https://t.co/gouDXwacax,en,[],['https://www.spglobal.com/marketintelligence/en/news-insights/trending/9w9_lhzkz25PmwDfpW1Irw2'],[],0,10,8,[],"['bmy', 'celg']",https://twitter.com/kristen_hallam/status/1100893202314395648,False,,0,,,,,,,,[],,,,
1100873490121527306,1100873490121527306,2019-02-28 03:11:07 IST,2019-02-28,03:11:07,+0530,15281391,thestreet,TheStreet,,Celgene $CELG falling more than 5% after Wellington says it doesn't back Bristol-Myers $BMY deal,en,[],[],[],0,2,5,[],"['celg', 'bmy']",https://twitter.com/TheStreet/status/1100873490121527306,False,,0,,,,,,,,[],,,,
1100870484340678656,1100870484340678656,2019-02-28 02:59:11 IST,2019-02-28,02:59:11,+0530,274233761,bradloncar,Brad Loncar,,I agree with Wellington on this Bristol-Celgene acquisition. Very hard to support it if you are on the Bristol side. Bristol management hasn't earned it. $BMY $CELG,en,[],[],[],5,3,27,[],"['bmy', 'celg']",https://twitter.com/bradloncar/status/1100870484340678656,False,,0,,,,,,,,[],,,,
1100869466538369025,1100869466538369025,2019-02-28 02:55:08 IST,2019-02-28,02:55:08,+0530,19717430,zbiotech,zach,,"$BMY $CELG  Bristol-Myers holder Wellington Management does not support the company‚Äôs proposed acquisition of Celgene   8% holder, #1",en,[],[],[],7,28,43,[],"['bmy', 'celg']",https://twitter.com/zbiotech/status/1100869466538369025,False,,0,,,,,,,,[],,,,
1100730478456422401,1100730478456422401,2019-02-27 17:42:51 IST,2019-02-27,17:42:51,+0530,3426014292,semodough,dough,,"Cowen Overwhelmingly, 91% of investors believe the BMY/CELG deal will close as planned, with 78% anticipating ‚â•70% chance of closing in Q3:19 as announced. Investors do not expect a bidder to emerge over the top on Celgene or for BMY to go into play.",en,[],[],[],1,2,8,[],[],https://twitter.com/semodough/status/1100730478456422401,False,,0,,,,,,,,[],,,,
1096594224273911809,1096594224273911809,2019-02-16 07:46:51 IST,2019-02-16,07:46:51,+0530,24890096,reutersdeals,Reuters Deals,,Starboard gauges Bristol-Myers shareholder support for Celgene deal  https://t.co/t5z4kowTHd @sveaherbst @gregroumeliotis $BMY $CELG,no,"[{'screen_name': 'sveaherbst', 'name': 'svea herbst', 'id': '361984022'}, {'screen_name': 'gregroumeliotis', 'name': 'greg roumeliotis', 'id': '783779510'}]",['https://reut.rs/2GKovy9'],[],0,7,4,[],"['bmy', 'celg']",https://twitter.com/reutersdeals/status/1096594224273911809,False,,0,,,,,,,,[],,,,
1095009933165297665,1095009933165297665,2019-02-11 22:51:27 IST,2019-02-11,22:51:27,+0530,19717430,zbiotech,zach,,*CELGENE AVOIDS PATENT OFFICE REVIEW OF THREE REVLIMID PATENTS  $CELG $BMY,en,[],[],[],1,4,5,[],"['celg', 'bmy']",https://twitter.com/zbiotech/status/1095009933165297665,False,,0,,,,,,,,[],,,,
1095006237509398530,1095006237509398530,2019-02-11 22:36:45 IST,2019-02-11,22:36:45,+0530,31546412,tradehawk,TradeHawk,,$CELG $RDY Celgene popping on denial of institution of '717 Revlimid IPR patent challenge trial by Dr. Reddy Labs.,en,[],[],[],0,9,7,[],"['celg', 'rdy']",https://twitter.com/TradeHawk/status/1095006237509398530,False,,0,,,,,,,,[],,,,
1092410658510065669,1092410658510065669,2019-02-04 18:42:51 IST,2019-02-04,18:42:51,+0530,102754598,johncendpts,John Carroll,,‚ÄòMost feared‚Äô activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B Celgene buyout? $BMY $CELG -2.25%  https://t.co/pksWNxLG72,en,[],['https://endpts.com/most-feared-activist-investor-in-america-has-zeroed-in-on-bristol-myers-squibb-is-he-planning-to-derail-the-74b-celgene-buyout/'],[],1,9,17,[],"['bmy', 'celg']",https://twitter.com/JohnCendpts/status/1092410658510065669,False,,0,,,,,,,,[],,,,
1091397856148291584,1091397856148291584,2019-02-01 23:38:20 IST,2019-02-01,23:38:20,+0530,2569742156,dpd_mergers,DealPointData - M&A,,"Bristol-Myers $BMY disclosed that it will pay a total of $137 mil in advisory fees to Morgan Stanley ($82 mil), Evercore ($30 mil) &amp; Dyal Co. ($25 mil) for advising on its $90 bil acqstn of Celgene $CELG; the $137 mil acquirer side total fee is the largest we have recorded (2/2)",en,[],[],[],0,4,9,[],"['bmy', 'celg']",https://twitter.com/DPD_Mergers/status/1091397856148291584,False,,0,,,,,,,,[],,,,
1091343432377880576,1091343432377880576,2019-02-01 20:02:05 IST,2019-02-01,20:02:05,+0530,102754598,johncendpts,John Carroll,,"Playing hardball, Bristol-Myers bought out a battered Celgene with last-minute terms sweetened in its favor $BMY $CELG  https://t.co/twaHHRgwDe",en,[],['https://endpts.com/playing-hardball-bristol-myers-bought-out-a-battered-celgene-with-last-minute-terms-sweetened-in-its-favor/'],[],1,1,6,[],"['bmy', 'celg']",https://twitter.com/JohnCendpts/status/1091343432377880576,False,,0,,,,,,,,[],,,,
1090218961353039872,1090218961353039872,2019-01-29 17:33:50 IST,2019-01-29,17:33:50,+0530,102754598,johncendpts,John Carroll,,Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech $CELG  https://t.co/4GTneS4nQ6,en,[],['https://endpts.com/celgene-rolls-along-with-another-epigenetic-preclinical-deal-featuring-a-canadian-biotech/'],[],1,9,16,[],['celg'],https://twitter.com/JohnCendpts/status/1090218961353039872,False,,0,,,,,,,,[],,,,
1089615526828027905,1089615526828027905,2019-01-28 01:36:00 IST,2019-01-28,01:36:00,+0530,274233761,bradloncar,Brad Loncar,,"Celgene also has a call listed on its website for Thursday at 9:00AM ET, although they haven't officially announced that in a press release. $CELG",en,[],[],[],2,1,11,[],['celg'],https://twitter.com/bradloncar/status/1089615526828027905,False,,0,,,,,,,,[],,,,
1087692571143475201,1087692571143475201,2019-01-22 18:14:51 IST,2019-01-22,18:14:51,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$CELG, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing  https://t.co/n0sCNLmuPg @matthewherper pens the definitive Celgene obit. This is a compelling read, starting with a cabbie's stock tip.",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/01/22/celgene-legacy-chutzpah-science-drug-pricing/'],[],2,11,31,[],['celg'],https://twitter.com/adamfeuerstein/status/1087692571143475201,False,,0,,,,,,,,[],,,,
1087169416771575812,1087169416771575812,2019-01-21 07:36:02 IST,2019-01-21,07:36:02,+0530,3426014292,semodough,dough,,JEFF $CELG $BMY Celgene - Thoughts on widening spread - has grown to notable 18-20% now‚Ä¶  https://t.co/Ex1mLbzLUl,en,[],[],['https://pbs.twimg.com/media/DxZm0W1V4AALE09.jpg'],0,4,17,[],"['celg', 'bmy']",https://twitter.com/semodough/status/1087169416771575812,False,,1,https://pbs.twimg.com/media/DxZm0W1V4AALE09.jpg,,,,,,,[],,,,
1087139713545392128,1087139713545392128,2019-01-21 05:38:00 IST,2019-01-21,05:38:00,+0530,3460109487,endpts,Endpoints News,,Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records  https://t.co/qKwyx9FOGb $CELG,en,[],['https://endpts.com/celgenes-top-20-upfront-hits-just-how-generous-was-celgene-in-dealmaking-lets-review-the-records/'],[],0,0,4,[],['celg'],https://twitter.com/endpts/status/1087139713545392128,False,,0,,,,,,,,[],,,,
1086292893915103232,1086292893915103232,2019-01-18 21:33:02 IST,2019-01-18,21:33:02,+0530,1330055544,benthefidler,Ben Fidler,,"Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups  https://t.co/wXQytzofd1 by @corielok $CELG $BMY @atlasventure",en,"[{'screen_name': 'corielok', 'name': 'corie lok', 'id': '14935412'}, {'screen_name': 'atlasventure', 'name': 'atlas venture', 'id': '26637792'}]",['https://xconomy.com/boston/2019/01/18/despite-buyout-celgene-dealmaking-rolls-on-with-kyn-obsidian-tie-ups/'],[],0,2,8,[],"['celg', 'bmy']",https://twitter.com/BentheFidler/status/1086292893915103232,False,,0,,,,,,,,[],,,,
1086004017078173701,1086004017078173701,2019-01-18 02:25:09 IST,2019-01-18,02:25:09,+0530,102754598,johncendpts,John Carroll,,Celgene related?  Scoop: Forma axes discovery biology team as part of a broader reorganization $CELG  https://t.co/Gn7hJCNWBt,en,[],['https://endpts.com/scoop-forma-axes-discovery-biology-team-as-part-of-a-broader-reorganization/'],[],1,6,7,[],['celg'],https://twitter.com/JohnCendpts/status/1086004017078173701,False,,0,,,,,,,,[],,,,
1085556062860820485,1085556062860820485,2019-01-16 20:45:08 IST,2019-01-16,20:45:08,+0530,475309726,tradestation,TradeStation,,"#Biotech stocks are off to a healthy start in 2019, thanks to some big-name #takeovers involving #Celgene $CELG and #BristolMyersSquibb $BMY, as well as #LoxoOncology $LOXO and #EliLilly $LLY. Check out the other names rising to the top.  https://t.co/7XLSKNK0Mw  https://t.co/biWmOkxREW",en,[],['https://bit.ly/2HdY71q'],['https://pbs.twimg.com/media/DxCrfEgWkAA6iwU.jpg'],0,6,29,"['biotech', 'takeovers', 'celgene', 'bristolmyerssquibb', 'loxooncology', 'elililly']","['celg', 'bmy', 'loxo', 'lly']",https://twitter.com/TradeStation/status/1085556062860820485,False,,1,https://pbs.twimg.com/media/DxCrfEgWkAA6iwU.jpg,,,,,,,[],,,,
1084879260651843586,1084860377828126720,2019-01-14 23:55:46 IST,2019-01-14,23:55:46,+0530,42782695,berkeleyjr,Berkeley Lovelace,,The 12 companies that the panel requested information from:  AbbVie $ABBV Amgen $AMGN AstraZeneca $AZN Celgene $CELG Eli Lilly $LLY Johnson &amp; Johnson $JNJ Mallinckrodt $MNK Novartis $NVS Novo Nordisk $NVO Pfizer $PFE Sanofi $SNY Teva Pharmaceuticals $TEVA,en,[],[],[],1,3,6,[],"['abbv', 'amgn', 'azn', 'celg', 'lly', 'jnj', 'mnk', 'nvs', 'nvo', 'pfe', 'sny', 'teva']",https://twitter.com/BerkeleyJr/status/1084879260651843586,False,,0,,,,,,,,[],,,,
1083772415476260864,1083772415476260864,2019-01-11 22:37:34 IST,2019-01-11,22:37:34,+0530,69421704,alexlash,Alex Lash,,"We survived #JPM19, and perhaps you did, too. Let's look back with our annual reporter's notebook, aka Notes from the Vortex. Price Apocalypse, Celgene Fallout &amp; More  https://t.co/KxX8IWz7BJ ‚Ä¶ with @BentheFidler and @sarahdc $CELG $BMY $REGN $ALNY $SRPT $STRO $JNCE",en,"[{'screen_name': 'benthefidler', 'name': 'ben fidler', 'id': '1330055544'}, {'screen_name': 'sarahdc', 'name': 'sarah de crescenzo', 'id': '17799992'}]",['https://xconomy.com/national/2019/01/11/notes-from-the-jpm19-vortex-price-apocalypse-celgene-fallout-more/'],[],0,3,7,['jpm19'],"['celg', 'bmy', 'regn', 'alny', 'srpt', 'stro', 'jnce']",https://twitter.com/alexlash/status/1083772415476260864,False,,0,,,,,,,,[],,,,
1083702236344209409,1083702236344209409,2019-01-11 17:58:42 IST,2019-01-11,17:58:42,+0530,884340618494959617,bioweeksf,BioWeekSF,,"Notes from the #JPM19 Vortex: Price Apocalypse, Celgene Fallout &amp; More    https://t.co/oURIT9NbIF via @xconomy $CELG $BMY $REGN $ALNY $SRPT $STRO $JNCE  #JPM2019 #BioWeekSF",en,"[{'screen_name': 'xconomy', 'name': 'xconomy', 'id': '29881875'}]",['https://xconomy.com/national/2019/01/11/notes-from-the-jpm19-vortex-price-apocalypse-celgene-fallout-more/'],[],0,3,6,"['jpm19', 'jpm2019', 'bioweeksf']","['celg', 'bmy', 'regn', 'alny', 'srpt', 'stro', 'jnce']",https://twitter.com/bioweeksf/status/1083702236344209409,False,,0,,,,,,,,[],,,,
1083695763304210432,1083695763304210432,2019-01-11 17:32:58 IST,2019-01-11,17:32:58,+0530,1330055544,benthefidler,Ben Fidler,,"Notes from the #JPMHC19 Vortex: Price Apocalypse, Celgene Fallout &amp; More  https://t.co/uiY01YpPwp with @alexlash and @sarahdc $CELG $BMY $REGN $ALNY $SRPT $STRO $JNCE",en,"[{'screen_name': 'alexlash', 'name': 'alex lash', 'id': '69421704'}, {'screen_name': 'sarahdc', 'name': 'sarah de crescenzo', 'id': '17799992'}]",['https://xconomy.com/national/2019/01/11/notes-from-the-jpm19-vortex-price-apocalypse-celgene-fallout-more/'],[],4,1,7,['jpmhc19'],"['celg', 'bmy', 'regn', 'alny', 'srpt', 'stro', 'jnce']",https://twitter.com/BentheFidler/status/1083695763304210432,False,,0,,,,,,,,[],,,,
1083044578222051328,1083044578222051328,2019-01-09 22:25:24 IST,2019-01-09,22:25:24,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @GileadSciences @abbvie @pfizer @Celgene @Roche  Sangamo will have HIV clinical data readout within 2 months.  Are you interested in an HIV Cure option? @SangamoTx wants to partner this pipeline.  https://t.co/u0bn7x2bvO  $SGMO $GILD $ABBV $PFE $CELG #JPM19,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",['https://clinicaltrials.gov/ct2/show/NCT02500849'],[],0,2,13,['jpm19'],"['sgmo', 'gild', 'abbv', 'pfe', 'celg']",https://twitter.com/Biotech2050/status/1083044578222051328,False,,0,,,,,,,,[],,,,
1082625458422788096,1082625458422788096,2019-01-08 18:39:58 IST,2019-01-08,18:39:58,+0530,102754598,johncendpts,John Carroll,,Lots of buzz at #JPM19 about Celgene of course. Consensus opinion I'm hearing: Alles and his crew caved rather than fight it out. The CVR is weak. The company changed from a winner to a loser in 18 months. It's all a damn shame. $CELG $BMY,en,[],[],[],8,9,59,['jpm19'],"['celg', 'bmy']",https://twitter.com/JohnCendpts/status/1082625458422788096,False,,0,,,,,,,,[],,,,
1082268118393802753,1082268118393802753,2019-01-07 19:00:01 IST,2019-01-07,19:00:01,+0530,34010976,bmsnews,Bristol Myers Squibb,,"Watch our Chairman and CEO Giovanni Caforio this morning on CNBC w/ @jimcramer &amp; @Celgene Chairman and CEO Mark Alles, discussing last week‚Äôs Celgene announcement and more, ~9:30 a.m. ET/6:30 a.m. PT from #JPM19 $BMY $CELG  https://t.co/5szWvORREt",en,"[{'screen_name': 'jimcramer', 'name': 'jim cramer', 'id': '14216123'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],['https://pbs.twimg.com/media/DwT9HkMWoAAo_RZ.jpg'],0,4,21,['jpm19'],"['bmy', 'celg']",https://twitter.com/bmsnews/status/1082268118393802753,False,,1,https://pbs.twimg.com/media/DwT9HkMWoAAo_RZ.jpg,,,,,,,[],,,,
1082253396395085824,1082253396395085824,2019-01-07 18:01:31 IST,2019-01-07,18:01:31,+0530,59393368,livesquawk,LiveSquawk,,Celgene:  $CELG -Reaffirms 2020 Outlook  -Sees FY19 Adjusted Share: $10.60-$10.80 -Sees FY20 Revenue:  $19-20Bln,en,[],[],[],0,3,5,[],['celg'],https://twitter.com/LiveSquawk/status/1082253396395085824,False,,0,,,,,,,,[],,,,
1082095433785245696,1082095433785245696,2019-01-07 07:33:50 IST,2019-01-07,07:33:50,+0530,34010976,bmsnews,Bristol Myers Squibb,,"Watch our Chairman and CEO Giovanni Caforio tomorrow morning on CNBC w/ @jimcramer &amp; @Celgene Chairman and CEO Mark Alles, discussing last week‚Äôs Celgene announcement and more, ~9:30 a.m. ET/6:30 a.m. PT from #JPM19 $BMY $CELG  https://t.co/A3cdhNznUz",en,"[{'screen_name': 'jimcramer', 'name': 'jim cramer', 'id': '14216123'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],['https://pbs.twimg.com/media/DwRfzpUWkAAL-jT.jpg'],0,10,17,['jpm19'],"['bmy', 'celg']",https://twitter.com/bmsnews/status/1082095433785245696,False,,1,https://pbs.twimg.com/media/DwRfzpUWkAAL-jT.jpg,,,,,,,[],,,,
1081168484921421824,1081168484921421824,2019-01-04 18:10:28 IST,2019-01-04,18:10:28,+0530,19717430,zbiotech,zach,,"*CELGENE, BRISTOL-MYERS DEAL HAS $2.2B TERMINATION FEE  $CELG $BMY",en,[],[],[],2,13,36,[],"['celg', 'bmy']",https://twitter.com/zbiotech/status/1081168484921421824,False,,0,,,,,,,,[],,,,
1080981205795856386,1080981205795856386,2019-01-04 05:46:17 IST,2019-01-04,05:46:17,+0530,33669217,kerrydolan,Kerry Dolan,,Bristol-Myers Squibb $BMY And Celgene's $CELG Big Winner? Los Angeles #Billionaire Patrick Soon-Shiong via @forbes  https://t.co/zqhm1pfJg7,en,"[{'screen_name': 'forbes', 'name': 'forbes', 'id': '91478624'}]",['https://www.forbes.com/sites/michelatindera/2019/01/03/bristol-myers-squibb-and-celgenes-big-winner-los-angeles-billionaire-patrick-soon-shiong/#1be63046423c'],[],0,4,12,['billionaire'],"['bmy', 'celg']",https://twitter.com/KerryDolan/status/1080981205795856386,False,,0,,,,,,,,[],,,,
1080940651175440385,1080940651175440385,2019-01-04 03:05:08 IST,2019-01-04,03:05:08,+0530,1022203640,michaelhgibney,Michael Gibney,,"Follow-up to the big news this morning, and lots to discuss at #JPM19: Bristol-Myers, Celgene to face crowded #cancer market together in $74B union | S&amp;P Global Market Intelligence $BMY $CELG  https://t.co/mbuPelU0Lh",en,[],['https://www.spglobal.com/marketintelligence/en/news-insights/trending/zc-VCQuDHHIRr4r3hBAyAw2'],[],0,7,6,"['jpm19', 'cancer']","['bmy', 'celg']",https://twitter.com/MichaelHGibney/status/1080940651175440385,False,,0,,,,,,,,[],,,,
1080933431633047552,1080933431633047552,2019-01-04 02:36:27 IST,2019-01-04,02:36:27,+0530,2272207286,hedgemind,HedgeMind,,$CELG Surprised to see that Celgene would agree to be acquired at this price. Was actually expecting its eventual turnaround. Steve Cohen's new buy would generate very little gain if any. See who are winners among top hedgies.   https://t.co/vD1HO86RzZ  https://t.co/hfLj2N6kR0,en,[],['https://hedgemind.com/stocks/CELG'],['https://pbs.twimg.com/media/DwA-6zJVYAEcnwA.jpg'],0,1,9,[],['celg'],https://twitter.com/HedgeMind/status/1080933431633047552,False,,1,https://pbs.twimg.com/media/DwA-6zJVYAEcnwA.jpg,,,,,,,[],,,,
1080932184414961664,1080932184414961664,2019-01-04 02:31:30 IST,2019-01-04,02:31:30,+0530,102094857,adamfeuerstein,Adam Feuerstein,,9 big takeaways from the $74 billion Bristol-Celgene deal  https://t.co/nsDmwtPuoW The gif illustration created by our @hoganalex is üëç $CELG $BMY,en,"[{'screen_name': 'hoganalex', 'name': 'alex hogan', 'id': '296572811'}]",['https://www.statnews.com/2019/01/03/9-big-takeaways-from-the-74-billion-bristol-celgene-deal/'],[],0,8,9,[],"['celg', 'bmy']",https://twitter.com/adamfeuerstein/status/1080932184414961664,False,,0,,,,,,,,[],,,,
1080892692450680832,1080892692450680832,2019-01-03 23:54:34 IST,2019-01-03,23:54:34,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Why Bristol-Myers Squibb‚Äôs Giovanni Caforio is buying Celgene, in his own words  https://t.co/SvQsJt7Gfo @matthewherper spoke with Caforio and $CELG CEO Mark Alles $BMY",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/01/03/why-bristol-myers-squibbs-giovanni-caforio-is-buying-celgene-in-his-own-words/'],[],1,3,11,[],"['celg', 'bmy']",https://twitter.com/adamfeuerstein/status/1080892692450680832,False,,0,,,,,,,,[],,,,
1080863914840092672,1080863914840092672,2019-01-03 22:00:13 IST,2019-01-03,22:00:13,+0530,50753411,ldtimmerman,Luke Timmerman,,"CELG shareholders get to celebrate. R&amp;D &amp; BD people, especially inside CELG and its solar system of partners, not so much. VC-backed startups will surely be hiring a bunch out of Celgene.",en,[],[],[],1,3,11,[],[],https://twitter.com/ldtimmerman/status/1080863914840092672,False,https://twitter.com/Dereklowe/status/1080842893311598592,0,,,,,,,,[],,,,
1080842893311598592,1080842893311598592,2019-01-03 20:36:41 IST,2019-01-03,20:36:41,+0530,17393219,dereklowe,Derek Lowe,,"Thoughts on the Celgene/Bristol-Myers Squibb deal - CELG's shareholders should celebrate, and their R&amp;D people should get braced:  https://t.co/eeOpZSc602",en,[],['https://blogs.sciencemag.org/pipeline/archives/2019/01/03/bristol-myers-squibb-and-celgene'],[],2,13,53,[],[],https://twitter.com/Dereklowe/status/1080842893311598592,False,,0,,,,,,,,[],,,,
1080839234523750400,1080839234523750400,2019-01-03 20:22:09 IST,2019-01-03,20:22:09,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,What happens now: 1. $PFE buys $GILD &amp; $SGMO 2. $PFE screws $BMY and makes a better offer for $CELG as it realizes that CC-92480 + CC-220 + BCMA will more than replenish revlimid patent hill  @pfizer @Celgene @bmsnews @GileadSciences @SangamoTx,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",[],[],0,3,7,[],"['pfe', 'gild', 'sgmo', 'pfe', 'bmy', 'celg']",https://twitter.com/Biotech2050/status/1080839234523750400,False,,0,,,,,,,,[],,,,
1080835233061224449,1080835233061224449,2019-01-03 20:06:15 IST,2019-01-03,20:06:15,+0530,15563814,loftus,Peter Loftus,,"Celgene shares jump 28%, Bristol-Myers drops 12% after news of Bristol's $74B acquisition of Celgene $CELG $BMY",en,[],[],[],1,5,7,[],"['celg', 'bmy']",https://twitter.com/Loftus/status/1080835233061224449,False,,0,,,,,,,,[],,,,
1080832740319211520,1080832740319211520,2019-01-03 19:56:20 IST,2019-01-03,19:56:20,+0530,1278852289,tradingnation,Trading Nation,,Shares of Celgene soaring in the premarket after Bristol-Myers agreed to buy the biotech company for $74 billion $CELG $BMY  https://t.co/TbHzqTNEm4,en,[],[],['https://pbs.twimg.com/media/Dv_jn0iX4AAQ9jm.png'],2,7,14,[],"['celg', 'bmy']",https://twitter.com/TradingNation/status/1080832740319211520,False,,1,https://pbs.twimg.com/media/Dv_jn0iX4AAQ9jm.png,,,,,,,[],,,,
1080818663316484097,1080818663316484097,2019-01-03 19:00:24 IST,2019-01-03,19:00:24,+0530,102754598,johncendpts,John Carroll,,"UPDATED: Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline $BMY $CELG  https://t.co/glLgaax4WU",en,[],['https://endpts.com/bristol-myers-inks-a-74b-deal-to-buy-out-celgene-expects-15b-a-year-from-late-stage-pipeline/'],[],0,8,17,[],"['bmy', 'celg']",https://twitter.com/JohnCendpts/status/1080818663316484097,False,,0,,,,,,,,[],,,,
1080814357360070657,1080814357360070657,2019-01-03 18:43:18 IST,2019-01-03,18:43:18,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,Celgene up 33% pre-market after Bristol-Myers said it would acquire the company for $74B. Check out @petenajarian's pitch for $CELG back in October,en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],7,16,65,[],['celg'],https://twitter.com/CNBCFastMoney/status/1080814357360070657,False,https://twitter.com/CNBCFastMoney/status/1057752108475314176,0,,,,,,,,[],,,,
1080809070091739136,1080809070091739136,2019-01-03 18:22:17 IST,2019-01-03,18:22:17,+0530,15563814,loftus,Peter Loftus,,"Bristol-Myers is buying Celgene, maker of blockbuster cancer drugs, for $74 billion $BMY $CELG  https://t.co/0qNfwNeU3d via @WSJ",en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['https://www.wsj.com/articles/bristol-myers-squibb-to-acquire-celgene-11546517754'],[],1,6,15,[],"['bmy', 'celg']",https://twitter.com/Loftus/status/1080809070091739136,False,,0,,,,,,,,[],,,,
1080808726595072002,1080808726595072002,2019-01-03 18:20:55 IST,2019-01-03,18:20:55,+0530,174385219,mariogabelli,Mario Gabelli,,Blockbuster cure ? ....not today for BMY owners ....Bristol Myers ( BMY) in Deal to buy Celgene ( CELG) for combo of cash($50) and stock (1 share) ...Plus a CVR ...,en,[],[],[],2,2,12,[],[],https://twitter.com/MarioGabelli/status/1080808726595072002,False,,0,,,,,,,,[],,,,
1080806051480518656,1080806051480518656,2019-01-03 18:10:17 IST,2019-01-03,18:10:17,+0530,1036018569711169537,lambojohnny,Johnny Lambo,,"VALUE always emerges!!! Celgene $CELG was one of my 5 favourite USA value stocks. üöÄüöÄ  It just got acquired this morning, stock is up over 30%!! $spy $xbi   https://t.co/IToC17s833",en,[],['https://www.wsj.com/articles/bristol-myers-squibb-to-acquire-celgene-11546517754?mod=e2tw'],[],3,1,17,[],"['celg', 'spy', 'xbi']",https://twitter.com/LamboJohnny/status/1080806051480518656,False,https://twitter.com/LamboJohnny/status/1070032661157171200,0,,,,,,,,[],,,,
1080803271613255680,1080803271613255680,2019-01-03 17:59:14 IST,2019-01-03,17:59:14,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal  https://t.co/T4ILLgj5Xh $BMY $CELG and first co-byline from Matt and me.,en,[],['https://www.statnews.com/2019/01/03/bristol-myers-to-acquire-celgene/'],[],1,51,86,[],"['bmy', 'celg']",https://twitter.com/adamfeuerstein/status/1080803271613255680,False,,0,,,,,,,,[],,,,
1080800892809555968,1080800892809555968,2019-01-03 17:49:47 IST,2019-01-03,17:49:47,+0530,102754598,johncendpts,John Carroll,,"Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline $BMY $CELG  https://t.co/glLgaax4WU",en,[],['https://endpts.com/bristol-myers-inks-a-74b-deal-to-buy-out-celgene-expects-15b-a-year-from-late-stage-pipeline/'],[],0,36,28,[],"['bmy', 'celg']",https://twitter.com/JohnCendpts/status/1080800892809555968,False,,0,,,,,,,,[],,,,
1080800182260940800,1080800182260940800,2019-01-03 17:46:58 IST,2019-01-03,17:46:58,+0530,1546201075,ibd_kshreve,Ken Shreve,,WOW...CNBC reporting that Bristol-Myers Squibb to acquire Celgene for $74 bil $CELG $BMY #biotech #biotechstocks,en,[],[],[],3,0,9,"['biotech', 'biotechstocks']","['celg', 'bmy']",https://twitter.com/IBD_KShreve/status/1080800182260940800,False,,0,,,,,,,,[],,,,
1080798286666190848,1080798286666190848,2019-01-03 17:39:26 IST,2019-01-03,17:39:26,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"$BMY just emerged as a new $SGMO suitor re allogeneic CAR-T , re Alzheimer Re $CELG Celgene zinc finger research ...",en,[],[],[],1,3,14,[],"['bmy', 'sgmo', 'celg']",https://twitter.com/_B_I_O_T_E_C_H_/status/1080798286666190848,False,https://twitter.com/_B_I_O_T_E_C_H_/status/976417304216047616,0,,,,,,,,[],,,,
1080797647945039873,1080797647945039873,2019-01-03 17:36:54 IST,2019-01-03,17:36:54,+0530,475524030,wallstjesus,JE$US,,"Bristol-Myers Squibb to acquire Celgene for $74B  https://t.co/DEuzFOpOz7 $BMY, $CELG  https://t.co/eJgwxIraOI",no,[],['https://seekingalpha.com/news/3420229?source=ansh'],['https://pbs.twimg.com/media/Dv_Dur0XcAAotqg.jpg'],2,2,7,[],"['bmy', 'celg']",https://twitter.com/WallStJesus/status/1080797647945039873,False,,1,https://pbs.twimg.com/media/Dv_Dur0XcAAotqg.jpg,,,,,,,[],,,,
1080797097891450881,1080797097891450881,2019-01-03 17:34:43 IST,2019-01-03,17:34:43,+0530,15281391,thestreet,TheStreet,,Breaking -- Bristol-Myers $BMY to Buy Celgene $CELG in Deal Valued at $74 Billion. More to follow on  https://t.co/o6IinmgxZm,en,[],['http://TheStreet.com'],[],2,11,18,[],"['bmy', 'celg']",https://twitter.com/TheStreet/status/1080797097891450881,False,,0,,,,,,,,[],,,,
1080796050447785984,1080796050447785984,2019-01-03 17:30:33 IST,2019-01-03,17:30:33,+0530,223589965,gantosj,Joe,,That's huge news for the sector $BMY Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company Celgen $CELG,en,[],[],[],2,0,14,[],"['bmy', 'celg']",https://twitter.com/GantosJ/status/1080796050447785984,False,,0,,,,,,,,[],,,,
1080795553309560832,1080795553309560832,2019-01-03 17:28:34 IST,2019-01-03,17:28:34,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$BMY *Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company. $CELG,en,[],[],[],6,31,55,[],"['bmy', 'celg']",https://twitter.com/BioStocks/status/1080795553309560832,False,,0,,,,,,,,[],,,,
1074575151818256384,1074575151818256384,2018-12-17 13:30:55 IST,2018-12-17,13:30:55,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @pfizer @NovartisScience @Celgene @sanofi @GileadSciences $PFE $GILD $CELG $NVS $SNY $SGMO has a new pipeline which could be very disruptive: CAR-Tregs for #autoimmune disorders and organ rejection. This article explains the potential. #WinterIsComing  https://t.co/YHVdcFsF0v,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}]",['https://singularityhub.com/2018/08/07/car-t-may-be-a-silver-bullet-against-cancer-and-heres-what-else-it-can-do/#sm.0000vcl47c1cvqcx6rhy2t9ilq314'],[],1,2,5,"['autoimmune', 'winteriscoming']","['pfe', 'gild', 'celg', 'nvs', 'sny', 'sgmo']",https://twitter.com/Biotech2050/status/1074575151818256384,False,,0,,,,,,,,[],,,,
1073216000391286784,1073216000391286784,2018-12-13 19:30:08 IST,2018-12-13,19:30:08,+0530,102754598,johncendpts,John Carroll,,Who needs venture backers? Bill Haney bags new deal cash from Celgene as his biotech upstart Dragonfly explores NK cell tech $CELG  https://t.co/R50IA2ahqI,en,[],['https://endpts.com/who-needs-venture-backers-bill-haney-bags-new-deal-cash-from-celgene-as-his-biotech-upstart-dragonfly-explores-nk-cell-tech/'],[],1,2,6,[],['celg'],https://twitter.com/JohnCendpts/status/1073216000391286784,False,,0,,,,,,,,[],,,,
1072177219177512961,1072177219177512961,2018-12-10 22:42:23 IST,2018-12-10,22:42:23,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @Celgene  We are at 5 year lows following a great #ASH18 presentation.  $CELG has to decide:  1. either be aggressive and buyout a number of companies like $SGMO $ZIOP $TGTX ... which are trading at very low valuations; or 2. Be bought out cheaply  SIESTA TIME IS OVER,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],[],0,1,14,['ash18'],"['celg', 'sgmo', 'ziop', 'tgtx']",https://twitter.com/Biotech2050/status/1072177219177512961,False,,0,,,,,,,,[],,,,
1069388516138860545,1069388516138860545,2018-12-03 06:01:05 IST,2018-12-03,06:01:05,+0530,102754598,johncendpts,John Carroll,,"New #ASH18: Bluebird and Celgene didn‚Äôt ‚Äúbreak‚Äù their next-gen BCMA CAR-T, so now they‚Äôll double down on the dose and root for real durability $BLUE $CELG  https://t.co/SgzyDu4Wwi",en,[],['https://endpts.com/ash18-bluebird-and-celgene-didnt-break-their-next-gen-bcma-car-t-so-now-theyll-double-down-on-the-dose-and-root-for-real-durability/'],[],0,7,10,['ash18'],"['blue', 'celg']",https://twitter.com/JohnCendpts/status/1069388516138860545,False,,0,,,,,,,,[],,,,
1067109653916438528,1067109653916438528,2018-11-26 23:05:42 IST,2018-11-26,23:05:42,+0530,1358146357,rudyhavenstein,"Rudy Havenstein, Transitory Base Effect.",,"Apparently, according to Judge, Celgene is the cheapest company in the history of the universe. $CELG  https://t.co/6q5X15JiVB",en,[],[],['https://pbs.twimg.com/media/Ds8ijT4U8AEEH1k.jpg'],1,3,8,[],['celg'],https://twitter.com/RudyHavenstein/status/1067109653916438528,False,,1,https://pbs.twimg.com/media/Ds8ijT4U8AEEH1k.jpg,,,,,,,[],,,,
1067046475140685825,1067046475140685825,2018-11-26 18:54:39 IST,2018-11-26,18:54:39,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,"$CELG at 6.5 times 2019 est. earnings, Celgene trades at the lowest P/E multiple in the history of #biotech - Jefferies. Reiterates Buy, PT $115",en,[],[],[],0,1,15,['biotech'],['celg'],https://twitter.com/BioStocks/status/1067046475140685825,False,,0,,,,,,,,[],,,,
1066784007822721024,1066784007822721024,2018-11-26 01:31:42 IST,2018-11-26,01:31:42,+0530,3426014292,semodough,dough,,JEFF Celgene Corp.  $CELG Trades at Lowest P/E in History of Biotech at 6.5x into '19E - Chart of the Week Rating  BUY Price Target $115.00,en,[],[],[],3,3,15,[],['celg'],https://twitter.com/semodough/status/1066784007822721024,False,,0,,,,,,,,[],,,,
1064180930393358338,1064180930393358338,2018-11-18 21:07:59 IST,2018-11-18,21:07:59,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,"Dear @Celgene $CELG $SGMO's platform through precise gene editing and coupled with the newly acquired @TxCellSA could cure #rheumatoid #arthritis, #crohnsdisease, &amp; #MultipleSclerosis. A cure in #diabetes type 1 also a possibility. Time to partner?",en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],[],0,1,9,"['rheumatoid', 'arthritis', 'crohnsdisease', 'multiplesclerosis', 'diabetes']","['celg', 'sgmo']",https://twitter.com/Biotech2050/status/1064180930393358338,False,https://twitter.com/JacobPlieth/status/1063108856476254208,0,,,,,,,,[],,,,
1062970874582700032,1062970874582700032,2018-11-15 12:59:40 IST,2018-11-15,12:59:40,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Good observations on a potential hostile bid of $SGMO @SangamoTx which should be passed on to the CEO's of @Celgene @GileadSciences @pfizer @Shireplc @Bioverativ @SanofiUS  $CELG $GILD $SHPG $SNY,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sanofius', 'name': 'sanofi us', 'id': '183033795'}]",[],[],1,3,8,[],"['sgmo', 'celg', 'gild', 'shpg', 'sny']",https://twitter.com/Biotech2050/status/1062970874582700032,False,https://twitter.com/MaxPowerNGS/status/1062837871093080064,0,,,,,,,,[],,,,
1062803817220186118,1062803817220186118,2018-11-15 01:55:50 IST,2018-11-15,01:55:50,+0530,102754598,johncendpts,John Carroll,,"#2 Celgene doubles down on Dragonfly‚Äôs natural killer tech, expanding into solid tumors with an injection of ‚Äòamplification capital‚Äô $CELG  https://t.co/c1ztF7CpyF",en,[],['https://endpts.com/celgene-doubles-down-on-dragonflys-natural-killer-tech-expanding-into-solid-tumors/'],[],0,5,9,[],['celg'],https://twitter.com/JohnCendpts/status/1062803817220186118,False,,0,,,,,,,,[],,,,
1062709510572134400,1062709510572134400,2018-11-14 19:41:06 IST,2018-11-14,19:41:06,+0530,849093025884237825,sanctuary_bio,Wilson Cheung,,"$CELG I'm going to try to be helpful @Celgene, I'm not sure the sell side has done an adequate job explaining why the market is furious with you folks, so I will be more direct.   Good luck with those sales projections. Don't get me wrong, I'd like to see success, but you know...  https://t.co/jxMgYlmsQS",en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],['https://pbs.twimg.com/media/Dr-Aht3VsAAMKKC.jpg'],1,1,19,[],['celg'],https://twitter.com/Sanctuary_Bio/status/1062709510572134400,False,,1,https://pbs.twimg.com/media/Dr-Aht3VsAAMKKC.jpg,,,,,,,[],,,,
1062697326903463936,1062697326903463936,2018-11-14 18:52:41 IST,2018-11-14,18:52:41,+0530,1330055544,benthefidler,Ben Fidler,,"Celgene Doubles Down on Dragonfly, Pays $50M to Expand #Cancer Pact  https://t.co/RKVIrSJLAr by @frankvinluan $CELG",en,"[{'screen_name': 'frankvinluan', 'name': 'frank vinluan', 'id': '211220879'}]",['https://xconomy.com/boston/2018/11/14/celgene-doubles-down-on-dragonfly-pays-50m-to-expand-cancer-pact/'],[],0,2,4,['cancer'],['celg'],https://twitter.com/BentheFidler/status/1062697326903463936,False,,0,,,,,,,,[],,,,
1062691925642358784,1062691925642358784,2018-11-14 18:31:13 IST,2018-11-14,18:31:13,+0530,102754598,johncendpts,John Carroll,,"Celgene doubles down on Dragonfly‚Äôs natural killer tech, expanding into solid tumors $CELG  https://t.co/c1ztF7CpyF",en,[],['https://endpts.com/celgene-doubles-down-on-dragonflys-natural-killer-tech-expanding-into-solid-tumors/'],[],0,5,10,[],['celg'],https://twitter.com/JohnCendpts/status/1062691925642358784,False,,0,,,,,,,,[],,,,
1058729812553023488,1058729812553023488,2018-11-03 20:07:12 IST,2018-11-03,20:07:12,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @Celgene  Dear @SangamoTx   It is about time that $CELG &amp; $SGMO enter into a collaboration in hematology to better exploit cereblons using the zinc finger platform. Have a look at this article:  https://t.co/YenE0UWyfX,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}]",['https://www.broadinstitute.org/news/thalidomide-reveals-path-targeting-undruggable-transcription-factors-cancer-treatment'],[],0,3,11,[],"['celg', 'sgmo']",https://twitter.com/Biotech2050/status/1058729812553023488,False,,0,,,,,,,,[],,,,
1057752108475314176,1057752108475314176,2018-11-01 03:22:09 IST,2018-11-01,03:22:09,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,"Biotech got battered this month, but @petenajarian is betting on a bounce for one stock: Celgene. $CELG  https://t.co/qhxAg0DEPZ",en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],6,15,53,[],['celg'],https://twitter.com/CNBCFastMoney/status/1057752108475314176,False,,1,https://pbs.twimg.com/media/Dq3j61SWwAAB39I.jpg,,,,,,,[],,,,
1055123943378612224,1055123943378612224,2018-10-24 21:18:46 IST,2018-10-24,21:18:46,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,$CELG  $77.00 current market price $12.50 2020 EPS estimate  Reporting tomorrow Q3 18 earnings. If 2020 numbers are reiterated than it is currently trading at x6 2020 EPS  #justsaying #HoldingOn  $IBB $XBI @pfizer @Roche @Celgene @GileadSciences,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}]",[],[],2,1,4,"['justsaying', 'holdingon']","['celg', 'ibb', 'xbi']",https://twitter.com/Biotech2050/status/1055123943378612224,False,,0,,,,,,,,[],,,,
1054869781118050305,1054869781118050305,2018-10-24 04:28:49 IST,2018-10-24,04:28:49,+0530,121885078,stockmktmedia,Stock Market Media,,Celgene's Revlimid shows positive effect in smoldering MM study $CELG üëá  https://t.co/HY5gKV92Jm,en,[],['https://seekingalpha.com/news/3399992-celgenes-revlimid-shows-positive-effect-smoldering-mm-study'],[],0,3,4,[],['celg'],https://twitter.com/StockMktMedia/status/1054869781118050305,False,,0,,,,,,,,[],,,,
1039238970989838341,1039238970989838341,2018-09-11 01:17:33 IST,2018-09-11,01:17:33,+0530,102754598,johncendpts,John Carroll,,"This is mostly another ding for $GSK -- Analyst offers Amgen a boost for its rival anti-BCMA BiTE, blemishing GSK as well as CAR-T rivals Celgene and bluebird $AMGN $CELG $BLUE  https://t.co/os0sokZFA9",en,[],['https://endpts.com/?p=168199&preview=true'],[],3,6,14,[],"['gsk', 'amgn', 'celg', 'blue']",https://twitter.com/JohnCendpts/status/1039238970989838341,False,,0,,,,,,,,[],,,,
1035263527269879808,1035263527269879808,2018-08-31 02:00:33 IST,2018-08-31,02:00:33,+0530,15568127,themotleyfool,The Motley Fool,,Celgene's price-to-sales and price-to-earnings ratios are near the lowest they‚Äôve been since 2012. Bargain price? $CELG  https://t.co/anOmUeKioM,en,[],['https://www.fool.com/investing/2018/08/29/3-top-healthcare-stocks-to-buy-right-now.aspx'],[],0,0,9,[],['celg'],https://twitter.com/themotleyfool/status/1035263527269879808,False,,0,,,,,,,,[],,,,
1034841876141092864,1034841876141092864,2018-08-29 22:05:04 IST,2018-08-29,22:05:04,+0530,3426014292,semodough,dough,,"$CELG Celgene call volume above normal and directionally bullish Bullish option flow detected in Celgene with 14,596 calls trading, 2x expected, and implied vol increasing over 1 point to 23.34%. 8/31 weekly 94 calls and 9/7 weekly 105 calls are the most active options",en,[],[],[],0,0,5,[],['celg'],https://twitter.com/semodough/status/1034841876141092864,False,,0,,,,,,,,[],,,,
1034597706394681346,1034597706394681346,2018-08-29 05:54:49 IST,2018-08-29,05:54:49,+0530,61342056,optionshawk,Joe Kunkle,,"Celgene $CELG large cup and handle as shares consolidate at 200 MA, rumors of its death appear exaggerated... chart via @IBDinvestors @marketsmith #IBDpartner ; sentiment improving w/ positive data headlines, some 2H catalysts  https://t.co/OarnQ5a39g  https://t.co/w69Xzcwk16",en,"[{'screen_name': 'ibdinvestors', 'name': 'investors.com', 'id': '21328656'}, {'screen_name': 'marketsmith', 'name': 'marketsmith', 'id': '272125054'}]",['http://goo.gl/daqmQz'],['https://pbs.twimg.com/media/DluhIOAXcAAGsnb.jpg'],1,9,30,['ibdpartner'],['celg'],https://twitter.com/OptionsHawk/status/1034597706394681346,False,,1,https://pbs.twimg.com/media/DluhIOAXcAAGsnb.jpg,,,,,,,[],,,,
1022192204058697728,1022192204058697728,2018-07-26 00:19:47 IST,2018-07-26,00:19:47,+0530,61342056,optionshawk,Joe Kunkle,,"Celgene $CELG afternoon buyers of 5,000 August $88 calls to open $2.06 to $2.30 sweeps into earnings",en,[],[],[],0,3,15,[],['celg'],https://twitter.com/OptionsHawk/status/1022192204058697728,False,,0,,,,,,,,[],,,,
1017442868666003456,1017442868666003456,2018-07-12 21:47:37 IST,2018-07-12,21:47:37,+0530,3426014292,semodough,dough,,"ISI $CELG seems that the newsflow on Celgene has taken a turn for the  https://t.co/4lLZ7PMS4L last couple of weeks, we saw the luspatercept Ph 3 studies hit.  Today, heard a formal announcement that Novartis‚Äô Gilenya patents have been upheld as valid through 2027.",en,[],['http://better.In'],[],2,2,8,[],['celg'],https://twitter.com/semodough/status/1017442868666003456,False,,0,,,,,,,,[],,,,
1016495280563343360,1016495280563343360,2018-07-10 07:02:15 IST,2018-07-10,07:02:15,+0530,3426014292,semodough,dough,,on IV Jefferies after close - Celgene $CELG Additional Good News on Luspatercept Should Help Build Confidence in Pipeline Rating BUY Price Target $115.00  https://t.co/LFIEXewC3N,en,[],[],['https://pbs.twimg.com/media/DhtRDz4X4AA5B4j.jpg'],0,7,11,[],['celg'],https://twitter.com/semodough/status/1016495280563343360,False,,1,https://pbs.twimg.com/media/DhtRDz4X4AA5B4j.jpg,,,,,,,[],,,,
1016434650531680256,1016434650531680256,2018-07-10 03:01:19 IST,2018-07-10,03:01:19,+0530,102754598,johncendpts,John Carroll,,A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data $CELG $XLRN  https://t.co/xKIYkaWgYh,en,[],['https://endpts.com/acceleron-and-celgene-score-in-second-phiii-study-of-anemia-drug-luspatercept/'],[],0,7,17,[],"['celg', 'xlrn']",https://twitter.com/JohnCendpts/status/1016434650531680256,False,,0,,,,,,,,[],,,,
1016428626001006592,1016428626001006592,2018-07-10 02:37:23 IST,2018-07-10,02:37:23,+0530,430841130,canuck2usa,CtheLightTrading,,Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia; Regulatory Submissions Planned In US And Europe In 1H 2019 $CELG  https://t.co/Kul3gUQMP1 @benzinga,en,"[{'screen_name': 'benzinga', 'name': 'benzinga', 'id': '44060322'}]",['https://pro.benzinga.com'],[],1,1,5,[],['celg'],https://twitter.com/canuck2usa/status/1016428626001006592,False,,0,,,,,,,,[],,,,
1012433171714052096,1012433171714052096,2018-06-29 02:00:52 IST,2018-06-29,02:00:52,+0530,19717430,zbiotech,zach,,$CELG $XLRN Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‚ÄòMEDALIST‚Äô Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes,en,[],[],[],0,6,17,[],"['celg', 'xlrn']",https://twitter.com/zbiotech/status/1012433171714052096,False,,0,,,,,,,,[],,,,
1008258675067277312,1008258675067277312,2018-06-17 13:32:55 IST,2018-06-17,13:32:55,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,#EHA23 WOW @CELGENE $CELG! Even Jesus is talking about bb2121! Stunned!   https://t.co/Cf0x1bJED0,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",['https://twitter.com/ecancer/status/1007521981561032704?s=19'],[],2,1,5,['eha23'],['celg'],https://twitter.com/Biotech2050/status/1008258675067277312,False,https://twitter.com/ecancer/status/1007521981561032704?s=19,0,,,,,,,,[],,,,
1006973725076525056,1006973725076525056,2018-06-14 00:26:59 IST,2018-06-14,00:26:59,+0530,102754598,johncendpts,John Carroll,,"So I talked to Faheem Hasnain about those $CELG remarks -- Blame the ozanimod fiasco on the Receptos team? Just wait a sec, says ex-CEO, who sold the company to Celgene for $7.2B  https://t.co/HUkb7RonlJ",en,[],['https://endpts.com/blame-the-ozanimod-fiasco-on-the-receptos-team-just-wait-a-sec-says-ex-ceo-who-sold-the-company-to-celgene-for-7-2b/'],[],1,4,11,[],['celg'],https://twitter.com/JohnCendpts/status/1006973725076525056,False,,0,,,,,,,,[],,,,
1006871937874788354,1006871937874788354,2018-06-13 17:42:31 IST,2018-06-13,17:42:31,+0530,6810242,bydavidcrow,David Crow,,The real story of how Celgene bungled all-important FDA app for new MS drug - one of biggest biotech shocks of 2018 $CELG  https://t.co/QLW8lPPFqb  https://t.co/1xXjOTW8Y0,en,[],['https://www.ft.com/content/642beb68-6db0-11e8-852d-d8b934ff5ffa'],"['https://pbs.twimg.com/media/Dfkf1-EU8AAgsNM.jpg', 'https://pbs.twimg.com/media/DfkgX8gU8AAlRMk.jpg']",3,10,30,[],['celg'],https://twitter.com/bydavidcrow/status/1006871937874788354,False,,1,https://pbs.twimg.com/media/Dfkf1-EU8AAgsNM.jpg,,,,,,,[],,,,
1006860843143835648,1006860843143835648,2018-06-13 16:58:26 IST,2018-06-13,16:58:26,+0530,102754598,johncendpts,John Carroll,,Top Celgene exec pins the blame for ozanimod fiasco on the Receptos team ‚Äî acquired 3 years ago $CELG h/t @bydavidcrow  https://t.co/LUdnKuVmrQ,en,"[{'screen_name': 'bydavidcrow', 'name': 'david crow', 'id': '6810242'}]",['https://endpts.com/top-celgene-exec-pins-the-blame-for-ozanimod-fiasco-on-the-receptos-team-acquired-3-years-ago/'],[],1,1,6,[],['celg'],https://twitter.com/JohnCendpts/status/1006860843143835648,False,,0,,,,,,,,[],,,,
1006397531708952578,1006397531708952578,2018-06-12 10:17:24 IST,2018-06-12,10:17:24,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,My message to $SGMO CEO following yesterday's annual shareholders meeting @SangamoTx @Pfizer @GileadSciences @Celgene $PFE $GILD $CELG $IBB $XBI   https://t.co/W3QGvr2vrO,en,"[{'screen_name': 'sangamotx', 'name': 'sangamo therapeutics', 'id': '809083633671643136'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",['https://www.investorvillage.com/smbd.asp?mb=1933&mn=105425&pt=msg&mid=18370002'],[],0,2,7,[],"['sgmo', 'pfe', 'gild', 'celg', 'ibb', 'xbi']",https://twitter.com/Biotech2050/status/1006397531708952578,False,,0,,,,,,,,[],,,,
1004696356131360769,1004696356131360769,2018-06-07 17:37:32 IST,2018-06-07,17:37:32,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @Celgene @pfizer @SanofiUS @NovartisScience  $CELG $PFE $SNY $NVS $BIIB  $SGMO just filled a patent application for #TAU and you better have a look at it especially para 0250. Given patent application has been filed they might be open for a deal.   https://t.co/9Z1hCDgxB4,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'sanofius', 'name': 'sanofi us', 'id': '183033795'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}]",['https://www.investorvillage.com/smbd.asp?mb=1933&mn=105147&pt=msg&mid=18358164'],[],0,4,10,['tau'],"['celg', 'pfe', 'sny', 'nvs', 'biib', 'sgmo']",https://twitter.com/Biotech2050/status/1004696356131360769,False,,0,,,,,,,,[],,,,
1003613858798424064,1003613858798424064,2018-06-04 17:56:04 IST,2018-06-04,17:56:04,+0530,370238655,jodigralnick,jodi gralnick,,ICYMI: $CELG @Celgene CEO Mark Alles talks EXCLUSIVELY to @megtirrell at #ASCO18 about  personalized immunotherapy treatment for cancer patients and @Celgene investor confidence and pipeline.  https://t.co/Oc91h45ZTg,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",['https://cnb.cx/2Jm0T4T'],[],1,6,7,['asco18'],['celg'],https://twitter.com/jodigralnick/status/1003613858798424064,False,,0,,,,,,,,[],,,,
1003435137906946048,1003435137906946048,2018-06-04 06:05:54 IST,2018-06-04,06:05:54,+0530,370238655,jodigralnick,jodi gralnick,,"SET YOUR ALARM: our kick-#ASCO LIVE coverage starts tomorrow on @SquawkCNBC, with $CELG CEO at 710amET and $BMY CEO at 810ET, both EXCLUSIVE with @megtirrell. Then throughout the day $AZN, $LOXO, $BPMC, $MRK, $RHHBY all live and exclusive from #ASCO18. @Celgene @bmsnews",en,"[{'screen_name': 'squawkcnbc', 'name': 'squawk box', 'id': '404422077'}, {'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}]",[],[],0,1,6,"['asco', 'asco18']","['celg', 'bmy', 'azn', 'loxo', 'bpmc', 'mrk', 'rhhby']",https://twitter.com/jodigralnick/status/1003435137906946048,False,,0,,,,,,,,[],,,,
1003308736855838720,1003308736855838720,2018-06-03 21:43:38 IST,2018-06-03,21:43:38,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$CELG $JUNO  Celgene Announces Updated Safety and Efficacy Data from the  TRANSCEND Trial of liso-cel (#JCAR017) in Patients with Relapsed or  Refractory B-cell non-Hodgkin Lymphoma at #ASCO18  https://t.co/IF81WOpsoi,en,[],['http://ir.celgene.com/releasedetail.cfm?ReleaseID=1069109'],[],0,2,5,"['jcar017', 'asco18']","['celg', 'juno']",https://twitter.com/_B_I_O_T_E_C_H_/status/1003308736855838720,False,,0,,,,,,,,[],,,,
1002893667164737537,1002893667164737537,2018-06-02 18:14:17 IST,2018-06-02,18:14:17,+0530,102754598,johncendpts,John Carroll,,"ICYMI: Bluebird, Celgene add a promising chapter to their success story with BCMA-targeting CAR-T ‚Äî but fall short for investors $BLUE $CELG  https://t.co/hbw5BgkXbm",en,[],['https://endpts.com/bluebird-celgene-add-another-promising-chapter-to-their-success-story-with-bcma-targeting-car-t-bb2121/'],[],0,2,8,[],"['blue', 'celg']",https://twitter.com/JohnCendpts/status/1002893667164737537,False,,0,,,,,,,,[],,,,
1002670448805543941,1002670448805543941,2018-06-02 03:27:18 IST,2018-06-02,03:27:18,+0530,102754598,johncendpts,John Carroll,,"Bluebird, Celgene add another promising chapter to their success story with BCMA-targeting CAR-T bb2121 #ASCO18 $CELG $BLUE  https://t.co/hbw5BgkXbm",en,[],['https://endpts.com/bluebird-celgene-add-another-promising-chapter-to-their-success-story-with-bcma-targeting-car-t-bb2121/'],[],3,28,34,['asco18'],"['celg', 'blue']",https://twitter.com/JohnCendpts/status/1002670448805543941,False,,0,,,,,,,,[],,,,
1002641744083800065,1002641744083800065,2018-06-02 01:33:14 IST,2018-06-02,01:33:14,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,$CELG CELGENE CORP - PHASE III OPTIMISMM STUDY MET ITS PRIMARY ENDPOINT OF PFS     #ASCO18,en,[],[],[],1,2,5,['asco18'],['celg'],https://twitter.com/_B_I_O_T_E_C_H_/status/1002641744083800065,False,,0,,,,,,,,[],,,,
999989742522585088,999989742522585088,2018-05-25 17:55:08 IST,2018-05-25,17:55:08,+0530,15568127,themotleyfool,The Motley Fool,,"Fact: A steady drumbeat of negative news has sucked the air out of Celgene stock. Postulate: Mr. Market is so focused on what‚Äôs recent, he‚Äôs ignoring the solid fundamentals. $CELG.  https://t.co/jMlVGZxO85",en,[],['https://www.fool.com/investing/2018/05/24/i-just-bought-my-first-new-stock-in-8-months-and-t.aspx'],[],0,3,20,[],['celg'],https://twitter.com/themotleyfool/status/999989742522585088,False,,0,,,,,,,,[],,,,
999978449929494528,999978449929494528,2018-05-25 17:10:15 IST,2018-05-25,17:10:15,+0530,3426014292,semodough,dough,,Jefferies - 5 things Celgene Corp. $CELG 5 Key Things: Next-gen Revlimid Coming...and BCMA Full Court Press  Rating BUY  Price Target $115.00  https://t.co/xTSBRR2oMm,en,[],[],['https://pbs.twimg.com/media/DeCjEe-UQAIkHg1.jpg'],0,1,12,[],['celg'],https://twitter.com/semodough/status/999978449929494528,False,,1,https://pbs.twimg.com/media/DeCjEe-UQAIkHg1.jpg,,,,,,,[],,,,
999613569166692352,999613569166692352,2018-05-24 17:00:21 IST,2018-05-24,17:00:21,+0530,884391852119642112,trading_mz,Mz Trading,,Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program $CELG,en,[],[],[],1,9,8,[],['celg'],https://twitter.com/trading_mz/status/999613569166692352,False,,0,,,,,,,,[],,,,
999269013132795905,999269013132795905,2018-05-23 18:11:12 IST,2018-05-23,18:11:12,+0530,744650100,drpaulydesantis,"Dr. Paul DeSantis, PharmD",,"Sell-Side Quote of the week from Bernstein: ""Celgene: Upgrading to Outperform; at some point you have to step up"" $CELG",en,[],[],[],2,1,9,[],['celg'],https://twitter.com/DrPaulyDeSantis/status/999269013132795905,False,,0,,,,,,,,[],,,,
998794364020117504,998794364020117504,2018-05-22 10:45:07 IST,2018-05-22,10:45:07,+0530,3424441204,bagholderquotes,Bag Holder,,‚ÄúInvesting it celgene was the biggest mistake of my life.‚Äù $CELG  https://t.co/MhzgEzKmt7,en,[],[],['https://pbs.twimg.com/tweet_video_thumb/DdxuLDiVAAANcmR.jpg'],3,0,9,[],['celg'],https://twitter.com/BagholderQuotes/status/998794364020117504,False,,1,https://pbs.twimg.com/tweet_video_thumb/DdxuLDiVAAANcmR.jpg,,,,,,,[],,,,
998793588078133249,998793588078133249,2018-05-22 10:42:02 IST,2018-05-22,10:42:02,+0530,3424441204,bagholderquotes,Bag Holder,,"‚ÄúThe biggest regret of my life was listening to the @themotleyfool and there daily recommendation and articles pumping Celgene... I really believed them, I‚Äôve lost almost everything.‚Äù $CELG  https://t.co/O5XGvPk30O",en,"[{'screen_name': 'themotleyfool', 'name': 'the motley fool', 'id': '15568127'}]",[],['https://pbs.twimg.com/media/DdxtePhU0AAXlWm.jpg'],2,1,13,[],['celg'],https://twitter.com/BagholderQuotes/status/998793588078133249,False,,1,https://pbs.twimg.com/media/DdxtePhU0AAXlWm.jpg,,,,,,,[],,,,
998793110531403776,998793110531403776,2018-05-22 10:40:08 IST,2018-05-22,10:40:08,+0530,3424441204,bagholderquotes,Bag Holder,,"‚ÄúMark Alles of Celgene... my family has lost half of our life savings because of you!!! I hope you die a slow, miserbale existence you piece of sh******‚Äù $CELG #BagHalfEmptyKindaGuy",en,[],[],[],1,0,7,['baghalfemptykindaguy'],['celg'],https://twitter.com/BagholderQuotes/status/998793110531403776,False,,0,,,,,,,,[],,,,
998656989751373824,998656989751373824,2018-05-22 01:39:15 IST,2018-05-22,01:39:15,+0530,102754598,johncendpts,John Carroll,,"Wrestling with setbacks, Celgene adds $65M discovery alliance with Evotec to beef up on new cancer drugs $CELG  https://t.co/fMnCd9GmFA",en,[],['https://endpts.com/wrestling-with-setbacks-celgene-adds-65m-discovery-alliance-with-evotec-to-beef-up-on-new-cancer-drugs/'],[],1,7,10,[],['celg'],https://twitter.com/JohnCendpts/status/998656989751373824,False,,0,,,,,,,,[],,,,
998650586060017664,998650586060017664,2018-05-22 01:13:48 IST,2018-05-22,01:13:48,+0530,3426014292,semodough,dough,,"$CELG  call volume above normal&amp;directionally bullish Bullish option flow detected in Celgene with 72,765 calls trading, 4x expected,implied vol increasing almost 4 points to 33.29%. Jan-19 80 calls and 5/25 weekly 78 calls are most active options, with total volume near 14,800",en,[],[],[],1,2,6,[],['celg'],https://twitter.com/semodough/status/998650586060017664,False,,0,,,,,,,,[],,,,
998570987464601602,998570987464601602,2018-05-21 19:57:30 IST,2018-05-21,19:57:30,+0530,102754598,johncendpts,John Carroll,,"I talked to George Golumbeski about his departure from Celgene, and his new plans for biotech $CELG  https://t.co/ihUkiSqXfE",en,[],['https://endpts.com/bd-chief-george-golumbeski-is-the-latest-top-exec-to-exit-celgene-during-management-overhaul/'],[],0,6,7,[],['celg'],https://twitter.com/JohnCendpts/status/998570987464601602,False,,0,,,,,,,,[],,,,
997140392611991554,997140392611991554,2018-05-17 21:12:50 IST,2018-05-17,21:12:50,+0530,588507814,scripmandy,Mandy Jackson,,$CELG $JNCE Thread: Have to wonder how many Celgene investors are demanding accountability for the company‚Äôs growing list of setbacks.  https://t.co/y3Mv0sD9sZ,en,[],['https://twitter.com/bradloncar/status/997094488995753984'],[],0,2,6,[],"['celg', 'jnce']",https://twitter.com/ScripMandy/status/997140392611991554,False,https://twitter.com/bradloncar/status/997094488995753984,0,,,,,,,,[],,,,
997106407446007808,997105664110493696,2018-05-17 18:57:47 IST,2018-05-17,18:57:47,+0530,57124794,annaedney,Anna Edney,,"Companies that top the naughty list: Celgene, Gilead, Novartis  $CELG $GILD $NOVN",en,[],[],[],2,5,13,[],"['celg', 'gild', 'novn']",https://twitter.com/annaedney/status/997106407446007808,False,,0,,,,,,,,[],,,,
997098631693062145,997094488995753984,2018-05-17 18:26:53 IST,2018-05-17,18:26:53,+0530,274233761,bradloncar,Brad Loncar,,"Another thing I‚Äôll say about this is I‚Äôve seen $CELG BD head talk about this Jounce deal at a conference and how to them this was special and they threw so much money at because it is ‚Äútargeted, biomarker driven etc‚Äù development. You have to wonder if Celgene has any clue.",en,[],[],[],9,7,45,[],['celg'],https://twitter.com/bradloncar/status/997098631693062145,False,,0,,,,,,,,[],,,,
992408284056444929,992408284056444929,2018-05-04 19:49:07 IST,2018-05-04,19:49:07,+0530,3426014292,semodough,dough,,$CELG Pipeline Updates: Celgene flagged several anticipated data readouts to be presented at ASCO 2017 including updated durability and safety data from the TRANSCEND study of JCAR017 in r/r NHL (the study completed enrollment in Apri,en,[],[],[],3,3,5,[],['celg'],https://twitter.com/semodough/status/992408284056444929,False,,0,,,,,,,,[],,,,
992366140654608385,992366140654608385,2018-05-04 17:01:39 IST,2018-05-04,17:01:39,+0530,439377281,boerseger,BioGer,,"$CELG Celgene Reports First Quarter 2018 Operating and Financial Results  - Q1:18 total net product sales of $3,531 million, increased 20% Y/Y  - Raising full-year 2018 revenue guidance to high end of previous range    https://t.co/CUg8XAf4xo",en,[],['https://www.businesswire.com/news/home/20180504005282/en/Celgene-Reports-Quarter-2018-Operating-Financial-Results'],[],0,11,7,[],['celg'],https://twitter.com/BoerseGer/status/992366140654608385,False,,0,,,,,,,,[],,,,
989489097239605250,989489097239605250,2018-04-26 18:29:19 IST,2018-04-26,18:29:19,+0530,102754598,johncendpts,John Carroll,,Celgene‚Äôs disclosures about ozanimod this week spur analysts‚Äô fears of a lengthy delay for a key drug $CELG (down 18% from January 1)  https://t.co/jxTVaexq7s,en,[],['https://endpts.com/celgenes-disclosures-about-ozanimod-this-week-spur-analysts-fears-of-a-lengthy-delay-for-a-key-drug/'],[],0,4,8,[],['celg'],https://twitter.com/JohnCendpts/status/989489097239605250,False,,0,,,,,,,,[],,,,
988713186357645312,988713186357645312,2018-04-24 15:06:07 IST,2018-04-24,15:06:07,+0530,43475268,bio_clouseau,M,,How far $CELG has fallen. When $AGIO $EPZM and $XLRN IPO'd in 2013 to be associated with Celgene seemed to be a badge of honor. Not anymore $PRTA,en,[],[],[],3,0,12,[],"['celg', 'agio', 'epzm', 'xlrn', 'prta']",https://twitter.com/bio_clouseau/status/988713186357645312,False,,0,,,,,,,,[],,,,
983384185288130560,983384185288130560,2018-04-09 22:10:34 IST,2018-04-09,22:10:34,+0530,274233761,bradloncar,Brad Loncar,,Sol Barer was asked about $CELG‚Äôs current business model of external innovation via partnerships. Said he can‚Äôt comment on Celgene specifically but in general believes R&amp;D is central to the business. Says you need to spend time doing work and understanding things well internally.  https://t.co/MIEAV0JVd0,en,[],[],['https://pbs.twimg.com/media/DaWutF1WsAAYLrr.jpg'],2,4,12,[],[],https://twitter.com/bradloncar/status/983384185288130560,False,,1,https://pbs.twimg.com/media/DaWutF1WsAAYLrr.jpg,,,,,,,[],,,,
983006889574354945,983006889574354945,2018-04-08 21:11:20 IST,2018-04-08,21:11:20,+0530,6810242,bydavidcrow,David Crow,,"Celgene hunting for deals to offset loss of Revlimid patents, weighing offers for Agios and Jounce, per advisers (with @JFK_America) $CELG $AGIO $JNCE  https://t.co/qB40XBzrBO",en,"[{'screen_name': 'jfk_america', 'name': 'james fontanella-khan', 'id': '110929302'}]",['https://www.ft.com/content/192c3774-390f-11e8-8b98-2f31af407cc8?desktop=true&segmentId=d8d3e364-5197-20eb-17cf-2437841d178a#myft:notification:instant-email:content'],[],3,28,24,[],"['celg', 'agio', 'jnce']",https://twitter.com/bydavidcrow/status/983006889574354945,False,,0,,,,,,,,[],,,,
981552064827482112,981552064827482112,2018-04-04 20:50:23 IST,2018-04-04,20:50:23,+0530,65681636,chessnwine,Chess,,$CELG Daily. Much like homebuilders some of large cap bios like Celgene have been so beaten-down they seem due to bounce even in a down tape  https://t.co/0zQAs1swO2,en,[],[],['https://pbs.twimg.com/media/DZ8sZo7U8AEhjYd.png'],0,0,7,[],['celg'],https://twitter.com/chessNwine/status/981552064827482112,False,,1,https://pbs.twimg.com/media/DZ8sZo7U8AEhjYd.png,,,,,,,[],,,,
980918307695071233,980918307695071233,2018-04-03 02:52:03 IST,2018-04-03,02:52:03,+0530,102754598,johncendpts,John Carroll,,"Command and control: In sudden revamp, Celgene CEO Alles bids his COO goodbye and looks to regain confidence with management shuffle $CELG  https://t.co/ezZUTuNwRx",en,[],['https://endpts.com/in-sudden-revamp-celgene-ceo-alles-bids-his-coo-goodbye-and-looks-to-regain-confidence-with-management-shuffle/'],[],0,2,7,[],['celg'],https://twitter.com/JohnCendpts/status/980918307695071233,False,,0,,,,,,,,[],,,,
978952846036127744,978952846036127744,2018-03-28 16:42:01 IST,2018-03-28,16:42:01,+0530,439377281,boerseger,BioGer,,$CELG Abide and Celgene Enter Worldwide License Agreement for ABX-1772  https://t.co/hoH2zHqDQz,en,[],['https://www.prnewswire.com/news-releases/abide-and-celgene-enter-worldwide-license-agreement-for-abx-1772-300620576.html'],[],0,8,6,[],['celg'],https://twitter.com/BoerseGer/status/978952846036127744,False,,0,,,,,,,,[],,,,
978720579887992832,978720579887992832,2018-03-28 01:19:04 IST,2018-03-28,01:19:04,+0530,3426014292,semodough,dough,,"ISI $CELG discussed in our patent deep dive, a potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018.  Based on our thought process around a recent court filing, the odds of settlement have gone up considerably ... but let me explain",en,[],[],[],1,6,8,[],['celg'],https://twitter.com/semodough/status/978720579887992832,False,,0,,,,,,,,[],,,,
976499185070624769,976499185070624769,2018-03-21 22:12:02 IST,2018-03-21,22:12:02,+0530,32450040,evaluatevantage,Evaluate Vantage,,"Amid mounting questions, Celgene keeps spending  https://t.co/PlLq1jy6jG $CELG $PRTA  https://t.co/er6nL7i862",en,[],['http://www.epvantage.com/Universal/View.aspx?type=Story&id=774382&isEPVantage=yes'],['https://pbs.twimg.com/media/DY04oOmXkAA5d3G.jpg'],0,7,7,[],"['celg', 'prta']",https://twitter.com/evaluatevantage/status/976499185070624769,False,,1,https://pbs.twimg.com/media/DY04oOmXkAA5d3G.jpg,,,,,,,[],,,,
976408379672465408,976408379672465408,2018-03-21 16:11:13 IST,2018-03-21,16:11:13,+0530,102754598,johncendpts,John Carroll,,"From the PM bureau -- $CELG dives into Alzheimer's: Celgene goes all-out on neurodegeneration and Alzheimer‚Äôs, triggering blockbuster deal with $150M in cash for Prothena  https://t.co/HaRBIRCpsS",en,[],['https://endpts.com/celgene-goes-all-out-on-neurodegeneration-and-alzheimers-triggering-blockbuster-deal-with-150m-in-cash-for-prothena/'],[],2,7,10,[],['celg'],https://twitter.com/JohnCendpts/status/976408379672465408,False,,0,,,,,,,,[],,,,
976361475924140032,976361475924140032,2018-03-21 13:04:50 IST,2018-03-21,13:04:50,+0530,18294197,fiercebiotech,FierceBiotech,,"Celgene is handing over $100 million up front and making a $50 million equity investment in Prothena. In return, it will get the exclusive right to license clinical assets in the U.S. when INDs are filed:  https://t.co/K2eRqn57Zi $CELG $PRTA",en,[],['http://ow.ly/JCXc30j4oP2'],[],0,10,9,[],"['celg', 'prta']",https://twitter.com/FierceBiotech/status/976361475924140032,False,,0,,,,,,,,[],,,,
976197025082630144,976197025082630144,2018-03-21 02:11:22 IST,2018-03-21,02:11:22,+0530,873399943,jacobplieth,Jacob Plieth,,I think we can honestly say we‚Äôve now reached peak Celgene. $CELG $PRTA,en,[],[],[],4,1,10,[],"['celg', 'prta']",https://twitter.com/JacobPlieth/status/976197025082630144,False,,0,,,,,,,,[],,,,
976195134827016192,976195134827016192,2018-03-21 02:03:51 IST,2018-03-21,02:03:51,+0530,17589068,alanhobbes,Alan Leong,,"#Prothena $PRTA announces neuroscience collaboration with #Celgene $CELG Congrats to @GGKinney , @tranbryannguyen @EllenRoseA2Z and Wagner Zago at Prothena -  https://t.co/52ulWsSOaq",en,"[{'screen_name': 'ggkinney', 'name': 'gene kinney', 'id': '4186301532'}, {'screen_name': 'tranbryannguyen', 'name': 'tran', 'id': '4147226244'}, {'screen_name': 'ellenrosea2z', 'name': 'ellen rose', 'id': '2557166011'}]",['http://bit.ly/2GOLshy'],[],0,0,6,"['prothena', 'celgene']","['prta', 'celg']",https://twitter.com/alanhobbes/status/976195134827016192,False,,0,,,,,,,,[],,,,
976188278817902592,976188278817902592,2018-03-21 01:36:37 IST,2018-03-21,01:36:37,+0530,126416038,odibro,Odi Bruckman,,$PRTA Global Neuroscience Research &amp; Development Collaboration with $CELG  for Novel Therapies for Patients with Neurodegenerative Diseases. Prothena to receive a $100 million upfront payment and a $50 million equity investment from Celgene,en,[],[],[],2,11,15,[],"['prta', 'celg']",https://twitter.com/odibro/status/976188278817902592,False,,0,,,,,,,,[],,,,
976187949703401474,976187949703401474,2018-03-21 01:35:18 IST,2018-03-21,01:35:18,+0530,102754598,johncendpts,John Carroll,,"Celgene goes all-out on neurodegeneration and Alzheimer‚Äôs, triggering blockbuster deal with $150M in cash for Prothena $CELG $PRTA   https://t.co/HaRBIRCpsS",en,[],['https://endpts.com/celgene-goes-all-out-on-neurodegeneration-and-alzheimers-triggering-blockbuster-deal-with-150m-in-cash-for-prothena/'],[],2,43,35,[],"['celg', 'prta']",https://twitter.com/JohnCendpts/status/976187949703401474,False,,0,,,,,,,,[],,,,
971378726385672193,971378726385672193,2018-03-07 19:05:10 IST,2018-03-07,19:05:10,+0530,15568127,themotleyfool,The Motley Fool,,"We all know the market can be irrationally exuberant. Well, it can overreact in the other direction too. (A few Foolish investors think it has with Celgene, Apache, and Verizon.) $APA $VZ $CELG  https://t.co/yP6EZ8mai7",en,[],['https://www.fool.com/investing/2018/03/06/3-growth-stocks-at-deep-value-prices.aspx'],[],0,4,25,[],"['apa', 'vz', 'celg']",https://twitter.com/themotleyfool/status/971378726385672193,False,,0,,,,,,,,[],,,,
971313626480029697,971313626480029697,2018-03-07 14:46:29 IST,2018-03-07,14:46:29,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,My thoughts on a $CELG @Celgene buyout of $TGTX @TGTherapeutics  https://t.co/q4TliRPIxT,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'tgtherapeutics', 'name': 'tg therapeutics', 'id': '439362597'}]",['https://www.investorvillage.com/smbd.asp?mb=341&mn=216920&pt=msg&mid=18072044'],[],1,0,5,[],"['celg', 'tgtx']",https://twitter.com/Biotech2050/status/971313626480029697,False,,0,,,,,,,,[],,,,
970600067286601728,970600067286601728,2018-03-05 15:31:03 IST,2018-03-05,15:31:03,+0530,102754598,johncendpts,John Carroll,,Celgene hands over $101M in cash to launch a research collaboration with protein player Vividion $CELG  https://t.co/9tgYSdzdWZ,en,[],['https://endpts.com/celgene-hands-over-101m-in-cash-to-launch-a-research-collaboration-with-protein-player-vividion/'],[],0,11,21,[],['celg'],https://twitter.com/JohnCendpts/status/970600067286601728,False,,0,,,,,,,,[],,,,
970342861895012352,970342861895012352,2018-03-04 22:29:01 IST,2018-03-04,22:29:01,+0530,205746285,dakotahappas,Dakota in Braintree (Steve Happas),,"As mentioned by @pharmamaven ""ONLY $ZIOP &amp;  $XON can CONTROL IL-12 &amp; Turn Cold tumors hot...proven in 3 SOLID TUMORS"" -  Dr David Sterling co founder $CELG Celgene ""If you can control IL-12 you have the holy grail of cancer medicine""",en,"[{'screen_name': 'pharmamaven', 'name': 'rc', 'id': '243795494'}]",[],[],0,8,20,[],"['ziop', 'xon', 'celg']",https://twitter.com/DakotaHappas/status/970342861895012352,False,,0,,,,,,,,[],,,,
969317528584400896,969315912271650816,2018-03-02 02:34:42 IST,2018-03-02,02:34:42,+0530,588507814,scripmandy,Mandy Jackson,,"#BiocomPartnering Hood: $CELG Celgene is a great partner. Could execute. Someone that could make the process [of getting fedratinib to market] go faster, not slower.",en,[],[],[],0,0,5,['biocompartnering'],['celg'],https://twitter.com/ScripMandy/status/969317528584400896,False,,0,,,,,,,,[],,,,
968635879437807621,968635879437807621,2018-02-28 05:26:04 IST,2018-02-28,05:26:04,+0530,274233761,bradloncar,Brad Loncar,,Celgene and BeiGene announced their collaboration on July 5 last year.  Price then: CELG $133 BGNE $52 Price now: CELG $89 BGNE $153  https://t.co/bpA82VH91v,en,[],['https://twitter.com/odibro/status/968622215406252032'],[],2,11,47,[],[],https://twitter.com/bradloncar/status/968635879437807621,False,https://twitter.com/odibro/status/968622215406252032,0,,,,,,,,[],,,,
968603842630778888,968603842630778888,2018-02-28 03:18:46 IST,2018-02-28,03:18:46,+0530,102754598,johncendpts,John Carroll,,Bad news: Celgene blasted again after the FDA kicks back their marketing application on blockbuster hopeful ozanimod $CELG -6.4%  https://t.co/Gr675UJl6q,en,[],['https://endpts.com/bad-news-celgene-blasted-again-after-the-fda-kicks-back-their-marketing-application-on-blockbuster-hopeful-ozanimod/'],[],2,7,8,[],['celg'],https://twitter.com/JohnCendpts/status/968603842630778888,False,,0,,,,,,,,[],,,,
964556227954003974,964556227954003974,2018-02-16 23:14:59 IST,2018-02-16,23:14:59,+0530,15211869,jamie_love,James Love,,"KEI opposition to the Celgene Acquisition of Juno‚Äã Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma  https://t.co/2SPsVZ86o2  $celg $juno $blue #tcell #bcma",en,[],['https://www.keionline.org/26089'],[],0,10,9,"['tcell', 'bcma']","['celg', 'juno', 'blue']",https://twitter.com/jamie_love/status/964556227954003974,False,,0,,,,,,,,[],,,,
964474638574157824,964471400223436801,2018-02-16 17:50:47 IST,2018-02-16,17:50:47,+0530,3426014292,semodough,dough,,WOW -BAML lists big boys that could be taken out -Mature Biotech‚Äù M&amp;A candidates (As of 02/14/18) $CELG Celgene Corporation $VRTX  $ALXN $INCY $LGND $RGEN $IBB $SPY,en,[],[],[],2,4,15,[],"['celg', 'vrtx', 'alxn', 'incy', 'lgnd', 'rgen', 'ibb', 'spy']",https://twitter.com/semodough/status/964474638574157824,False,,0,,,,,,,,[],,,,
964437462893453312,964437462893453312,2018-02-16 15:23:04 IST,2018-02-16,15:23:04,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,#genome #editing to #cure #HIV #infection (Using $SGMO Zinc finger)  @GileadSciences @abbvie @pfizer @bmsnews @Celgene @NovartisScience @VasNarasimhan @Amgen @biogen @sanofi @Roche  $GILD $ABBV $PFE $BMY $CELG $NVS $AMGN $BIIB $SNY $RHHBY   https://t.co/irVjPxJyJJ,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'bmsnews', 'name': 'bristol myers squibb', 'id': '34010976'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'vasnarasimhan', 'name': 'vas narasimhan', 'id': '723488741348782080'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}]",['https://www.youtube.com/watch?v=WPp-ip0Nwyk'],[],1,4,7,"['genome', 'editing', 'cure', 'hiv', 'infection']","['sgmo', 'gild', 'abbv', 'pfe', 'bmy', 'celg', 'nvs', 'amgn', 'biib', 'sny', 'rhhby']",https://twitter.com/Biotech2050/status/964437462893453312,False,,0,,,,,,,,[],,,,
963752690965729281,963752690965729281,2018-02-14 18:02:01 IST,2018-02-14,18:02:01,+0530,82162291,avidresearch,avidresearch,,$CELG Celgene: Open-Ended Buyback Program Effective Immediately. think they add a ton below $100,en,[],[],[],1,4,10,[],['celg'],https://twitter.com/avidresearch/status/963752690965729281,False,,0,,,,,,,,[],,,,
963287084516732929,950402598363893762,2018-02-13 11:11:52 IST,2018-02-13,11:11:52,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@DrPaulyDeSantis @dhsmcmurtrie @CGrantWSJ If $CELG achieves $12.50 EPS (which it will beat); maintains 20% EPS CAGR (which it will exceed); &amp; have 770M sharecount (which will be much less) then valuation is = $12.5 x 20 x 770M = $192B = $250 per share @Celgene is preparing for second generation Revlimid = no patent cliff,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],[],1,0,7,[],['celg'],https://twitter.com/Biotech2050/status/963287084516732929,False,,0,,,,,,,,"[{'screen_name': 'DrPaulyDeSantis', 'name': 'Dr. Paul DeSantis, PharmD', 'id': '744650100'}, {'screen_name': 'CGrantWSJ', 'name': 'Charley Grant', 'id': '3043828834'}]",,,,
962721928019460097,962721928019460097,2018-02-11 21:46:08 IST,2018-02-11,21:46:08,+0530,243795494,pharmamaven,rc,,"Motley Fool - Better Buy: $AMG or $CELG -Celgene is dirt cheap, with shares trading at only 9 times expected earnings. If you're looking for growth at a great price, you won't find too many better stocks than Celgene.  https://t.co/rwF0nThFiY $IBB $BTK $NBI $XBI $BIIB $GILD $PFE",en,[],['https://www.fool.com/investing/2018/02/11/better-buy-amgen-inc-vs-celgene.aspx'],[],0,4,12,[],"['amg', 'celg', 'ibb', 'btk', 'nbi', 'xbi', 'biib', 'gild', 'pfe']",https://twitter.com/pharmamaven/status/962721928019460097,False,,0,,,,,,,,[],,,,
961878767282081792,961878767282081792,2018-02-09 13:55:43 IST,2018-02-09,13:55:43,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,"If $CELG CEO used $275K+ of own personal funds to buy 3,260 shares, he surely would also: 1. Tell the CFO to execute all remaining $800M buyback 2. Ask @celgene BOD to increase buyback 3. Seriously consider an advance share repurchase program with a broker  https://t.co/ll4YnH76kg",en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",['http://ir.celgene.com/secfiling.cfm?filingid=1209191-18-8456&cik=816284'],[],0,1,4,[],['celg'],https://twitter.com/Biotech2050/status/961878767282081792,False,,0,,,,,,,,[],,,,
961713382712803328,961713382712803328,2018-02-09 02:58:32 IST,2018-02-09,02:58:32,+0530,884391852119642112,trading_mz,Mz Trading,,*CRISPR THERAPEUTICS HOLDER CELGENE CUTS STAKE TO 6.1% $CRSP $CELG,en,[],[],[],0,7,7,[],"['crsp', 'celg']",https://twitter.com/trading_mz/status/961713382712803328,False,,0,,,,,,,,[],,,,
961233180119437313,961233180119437313,2018-02-07 19:10:23 IST,2018-02-07,19:10:23,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear $GILD $PFE $CELG $ABBV $BIIB $NVS $AMGN $RHHBY Successful #geneediting requires that there are no significant adverse events &amp; these: 1. Precision  2. Specificity 3. Efficiency  Only $SGMO can help you achieve this @GileadSciences  @Celgene @pfizer @Roche @abbvie @Amgen  https://t.co/jdtY5ZIDNM,en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}]",[],['https://pbs.twimg.com/media/DVb8e4rX0AAEwZY.jpg'],1,6,12,['geneediting'],"['gild', 'pfe', 'celg', 'abbv', 'biib', 'nvs', 'amgn', 'rhhby', 'sgmo']",https://twitter.com/Biotech2050/status/961233180119437313,False,,1,https://pbs.twimg.com/media/DVb8e4rX0AAEwZY.jpg,,,,,,,[],,,,
960926918588579841,960926918588579841,2018-02-06 22:53:25 IST,2018-02-06,22:53:25,+0530,243795494,pharmamaven,rc,,"Oppenheimer - Celgene $CELG Announces Positive Results for Pomalyst, Ahead of Schedule. Outperform 12-18 month target price $163 ($69 and 74% upside to CURRENT PRICE IS $94) Time to add $CELG   $IBB $BTK $XBI $NBI  https://t.co/M7R4ZHsJye",en,[],['https://www.investorvillage.com/smbd.asp?mb=341&mn=216229&pt=msg&mid=17966744'],[],0,1,10,[],"['celg', 'celg', 'ibb', 'btk', 'xbi', 'nbi']",https://twitter.com/pharmamaven/status/960926918588579841,False,,0,,,,,,,,[],,,,
960914417301860353,960914417301860353,2018-02-06 22:03:44 IST,2018-02-06,22:03:44,+0530,243795494,pharmamaven,rc,,$CELG way oversold - time to add on market dip. Over 30 Celgene 2018 catalysts from JMP report  https://t.co/jCZu5fozq2 $IBB $XBI $BTK,en,[],['https://www.investorvillage.com/smbd.asp?mb=341&mn=216240&pt=msg&mid=17967420'],[],0,1,10,[],"['celg', 'ibb', 'xbi', 'btk']",https://twitter.com/pharmamaven/status/960914417301860353,False,,0,,,,,,,,[],,,,
960522422305918977,960522422305918977,2018-02-05 20:06:05 IST,2018-02-05,20:06:05,+0530,746441781588426752,ambertongpw,Amber Tong,,blow by blow breakdown by @JohnCendpts &gt;&gt; Anatomy of a $9B buyout: Celgene‚Äôs quick turn from Juno‚Äôs close collaborator to new owner $CELG -  https://t.co/5WZRkHfFJW,en,"[{'screen_name': 'johncendpts', 'name': 'john carroll', 'id': '102754598'}]",['https://endpts.com/anatomy-of-a-9b-buyout-celgenes-quick-turn-from-junos-close-collaborator-to-new-owner/'],[],0,7,9,[],['celg'],https://twitter.com/AmberTongPW/status/960522422305918977,False,,0,,,,,,,,[],,,,
959548257889288192,959548257889288192,2018-02-03 03:35:06 IST,2018-02-03,03:35:06,+0530,6810242,bydavidcrow,David Crow,,"Celgene's negotiating strategy with Juno was, erm, interesting: $CELG went straight in at $80 (!); agreed to $86 to start due dil; tried to backtrack from $86; then got bid up to $87 by $JUNO. Was pretty much bidding against itself. No other serious parties #distressedbuyer",en,[],[],[],2,5,14,['distressedbuyer'],"['celg', 'juno']",https://twitter.com/bydavidcrow/status/959548257889288192,False,,0,,,,,,,,[],,,,
959546977917612033,959546977917612033,2018-02-03 03:30:01 IST,2018-02-03,03:30:01,+0530,576436187,carolineylchen,Caroline Chen,,"$CELG $JUNO negotiations started with Celgene offer of $80/share, according to filing. Deal was struck at $87/share.",en,[],[],[],0,4,9,[],"['celg', 'juno']",https://twitter.com/CarolineYLChen/status/959546977917612033,False,,0,,,,,,,,[],,,,
958117088190660609,958117088190660609,2018-01-30 04:48:09 IST,2018-01-30,04:48:09,+0530,102754598,johncendpts,John Carroll,,"After a legendary stint at Celgene‚Äôs helm, biopharma vet Bob Hugin is on his way out ‚Äî as Senate race rumors swirl $CELG  https://t.co/AyBIJGgoKW",en,[],['https://endpts.com/after-a-legendary-stint-at-celgenes-helm-biopharma-vet-bob-hugin-is-on-his-way-out-as-senate-race-rumors-swirl/'],[],0,6,7,[],['celg'],https://twitter.com/JohnCendpts/status/958117088190660609,False,,0,,,,,,,,[],,,,
957024151767728128,957024151767728128,2018-01-27 04:25:13 IST,2018-01-27,04:25:13,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,"Celgene Says Juno, Impact Deals Won't Be Its Last   https://t.co/xTFfL4Xvw5  $CELG",en,[],['https://search.app.goo.gl/Dd72'],[],0,6,10,[],['celg'],https://twitter.com/OphirGottlieb/status/957024151767728128,False,,0,,,,,,,,[],,,,
956886730044530688,956886730044530688,2018-01-26 19:19:09 IST,2018-01-26,19:19:09,+0530,102754598,johncendpts,John Carroll,,"Behind the deal spree, Celgene continues to cautiously explore neurosciences $CELG  https://t.co/zlQzvwgivS",en,[],['https://endpts.com/behind-the-deal-spree-celgene-continues-to-cautiously-explore-neurosciences/'],[],0,2,9,[],['celg'],https://twitter.com/JohnCendpts/status/956886730044530688,False,,0,,,,,,,,[],,,,
956507334137778176,956506221728686089,2018-01-25 18:11:34 IST,2018-01-25,18:11:34,+0530,3426014292,semodough,dough,,"$CELG Operating cash flow was $5,246 million for 2017, an increase of 26 percent compared to 2016. For the full-year 2017, Celgene purchased approximately $3,911 million of its common shares. As of December 31, 2017, had $822 million remaining under the existing share repurchase",en,[],[],[],1,5,7,[],['celg'],https://twitter.com/semodough/status/956507334137778176,False,,0,,,,,,,,[],,,,
956282578159521794,956281976981458944,2018-01-25 03:18:28 IST,2018-01-25,03:18:28,+0530,47678782,megtirrell,Meg Tirrell,,"$CELG was partnered with what was then described as ""tiny"" $BLUE.   And $NVS CEO forecast growing competition from CELG: ""You look at a company like Celgene, and you know they're going to figure it out.""",en,[],[],[],1,5,8,[],"['celg', 'blue', 'nvs']",https://twitter.com/megtirrell/status/956282578159521794,False,,0,,,,,,,,[],,,,
955893690077253633,955893690077253633,2018-01-24 01:33:10 IST,2018-01-24,01:33:10,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @pfizer @GileadSciences @Celgene @Shireplc @NovartisScience @sanofi @Amgen @roche @abbvie Please be aware of the patent granted today to $SGMO before you enter into an agreement with any #CRISPR Company $PFE $GILD $CELG $SHPG $NVS $SNY $RHBBY $ABBV    https://t.co/H1Vwva4Wd2,en,"[{'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'novartisscience', 'name': 'novartis science', 'id': '2260514101'}, {'screen_name': 'sanofi', 'name': 'sanofi', 'id': '35846368'}, {'screen_name': 'amgen', 'name': 'amgen', 'id': '28436760'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}]",['https://twitter.com/_B_I_O_T_E_C_H_/status/955871845697380352'],[],0,3,10,['crispr'],"['sgmo', 'pfe', 'gild', 'celg', 'shpg', 'nvs', 'sny', 'rhbby', 'abbv']",https://twitter.com/Biotech2050/status/955893690077253633,False,https://twitter.com/_B_I_O_T_E_C_H_/status/955871845697380352,0,,,,,,,,[],,,,
955824202623352833,955824202623352833,2018-01-23 20:57:02 IST,2018-01-23,20:57:02,+0530,274233761,bradloncar,Brad Loncar,,Both $CELG and EMD Serono highlight IDO and LAG-3 as promising targets. Celgene‚Äôs Stanley Frankel also mentions ICOS and TIGIT but says they aren‚Äôt validated yet.  https://t.co/QUTiC0wBU8,en,[],[],['https://pbs.twimg.com/media/DUPFC6sW0AA_XZX.jpg'],1,3,11,[],['celg'],https://twitter.com/bradloncar/status/955824202623352833,False,,1,https://pbs.twimg.com/media/DUPFC6sW0AA_XZX.jpg,,,,,,,[],,,,
955824200564035584,955824200564035584,2018-01-23 20:57:02 IST,2018-01-23,20:57:02,+0530,274233761,bradloncar,Brad Loncar,,Stanley Frankel of $CELG says a big reason behind their deal with $BGNE was so Celgene could run its own solid tumor combos unencumbered.  https://t.co/MPyKtHreMp,en,[],[],['https://pbs.twimg.com/media/DUPFC2HW0AAu-Au.jpg'],0,3,6,[],"['celg', 'bgne']",https://twitter.com/bradloncar/status/955824200564035584,False,,1,https://pbs.twimg.com/media/DUPFC2HW0AAu-Au.jpg,,,,,,,[],,,,
955576438077390849,955576438077390849,2018-01-23 04:32:31 IST,2018-01-23,04:32:31,+0530,3166329193,robertlkruse,"Robert Kruse, MD, PhD",,"Hope the #HBV CAR-T IP I filed with $CELG finds a good new home in partnership with $JUNO after the buyout. Celgene now has control of academic research output from @fredhutch, @sloan_kettering, and @bcmhouston.",en,"[{'screen_name': 'fredhutch', 'name': 'fred hutch', 'id': '16645335'}, {'screen_name': 'sloan_kettering', 'name': 'memorial sloan kettering cancer center', 'id': '27295244'}, {'screen_name': 'bcmhouston', 'name': 'bcmhouston', 'id': '34299110'}]",[],[],0,2,7,['hbv'],"['celg', 'juno']",https://twitter.com/RobertLKruse/status/955576438077390849,False,,0,,,,,,,,[],,,,
955554096412491777,955554096412491777,2018-01-23 03:03:44 IST,2018-01-23,03:03:44,+0530,2176983931,ronniemoas,Ronnie Moas | Nomad | Stocks | BTC | Charity,,#GeneralElectric $GE now down 50% since I slapped a Sell recommendation on it last year ... My #healthcare sector recommendation $JUNO taken over by $CELG #Celgene today ... now up 75% for us in the last week ... sign up at  https://t.co/7gPrQKWFiY / top ten ranking 2008-2017.,en,[],['http://www.standpointresearch.com'],[],1,1,20,"['generalelectric', 'healthcare', 'celgene']","['ge', 'juno', 'celg']",https://twitter.com/RonnieMoas/status/955554096412491777,False,,0,,,,,,,,[],,,,
955553517170757632,955553517170757632,2018-01-23 03:01:26 IST,2018-01-23,03:01:26,+0530,3426014292,semodough,dough,,JMP $EDIT $CELG  $9bln Acquisition of JUNO Positive for Editas PT 40 believe that Celgene is committed to engineered cell medicines and we anticipate the acquisition to accelerate and expand Editas‚Äô ability to advance engineered T cell medicines to market.,en,[],[],[],1,3,7,[],"['edit', 'celg']",https://twitter.com/semodough/status/955553517170757632,False,,0,,,,,,,,[],,,,
955514419982798848,955514419982798848,2018-01-23 00:26:04 IST,2018-01-23,00:26:04,+0530,102754598,johncendpts,John Carroll,,Web traffic tells the story -- top story today: UPDATED: Celgene bags CAR-T player Juno in $9B buyout as biotech M&amp;A suddenly explodes $CELG $JUNO  https://t.co/vA71PfFOQ6,en,[],['https://endpts.com/celgene-bags-car-t-player-juno-in-9b-buyout-as-biotech-ma-suddenly-explodes/'],[],0,12,18,[],"['celg', 'juno']",https://twitter.com/JohnCendpts/status/955514419982798848,False,,0,,,,,,,,[],,,,
955473311227633664,955473311227633664,2018-01-22 21:42:43 IST,2018-01-22,21:42:43,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,$SGMO has the potential to possibly cure a number of #RareDiseases plus has potential in #HIV + CAR T + TCR + #oncology + #Alzheimer ...  Do you think that the current $1.7B market cap is appropriate @Celgene @pfizer @GileadSciences @Shireplc $PFE $GILD $CELG $SHPG ? #justasking,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}]",[],[],0,5,12,"['rarediseases', 'hiv', 'oncology', 'alzheimer', 'justasking']","['sgmo', 'pfe', 'gild', 'celg', 'shpg']",https://twitter.com/Biotech2050/status/955473311227633664,False,,0,,,,,,,,[],,,,
955464720793919488,955464720793919488,2018-01-22 21:08:35 IST,2018-01-22,21:08:35,+0530,61342056,optionshawk,Joe Kunkle,,"Celgene $CELG bouncing to day highs and green after its deal for JUNO and seeing 5,500 February $106 calls open $2.18 to $2.30",en,[],[],[],1,2,10,[],['celg'],https://twitter.com/OptionsHawk/status/955464720793919488,False,,0,,,,,,,,[],,,,
955457724292190208,955457724292190208,2018-01-22 20:40:47 IST,2018-01-22,20:40:47,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"Leerink $CELG "" Celgene continues to invest in technological advances in the field, and it is not supplanted by other breakthroughs such as #in #vivo #gene #editing "" ---&gt; and thats ONLY $SGMO !!  https://t.co/IT5nHukP6F",en,[],[],['https://pbs.twimg.com/media/DUJ3iS0WsAAp1hB.jpg'],0,5,7,"['in', 'vivo', 'gene', 'editing']","['celg', 'sgmo']",https://twitter.com/_B_I_O_T_E_C_H_/status/955457724292190208,False,,1,https://pbs.twimg.com/media/DUJ3iS0WsAAp1hB.jpg,,,,,,,[],,,,
955439395976372225,955439395976372225,2018-01-22 19:27:57 IST,2018-01-22,19:27:57,+0530,349249475,gerberkawasaki,Ross Gerber,,"Big biotech deal. Hot space. Celgene to Buy Juno for $9 Billion, Signaling Cancer Aspirations $celg $juno   https://t.co/lbIEpXOKBA",en,[],['https://www.bloomberg.com/news/articles/2018-01-22/celgene-to-buy-juno-for-9-billion-signaling-cancer-aspirations'],[],2,1,6,[],"['celg', 'juno']",https://twitter.com/GerberKawasaki/status/955439395976372225,False,,0,,,,,,,,[],,,,
955437938283827200,955437938283827200,2018-01-22 19:22:10 IST,2018-01-22,19:22:10,+0530,23892927,danamattioli,Dana Mattioli,,Two WSJ Scoops confirmed this morning: Celgene to buy Juno for $9B  https://t.co/Et8MDDQLJH &amp; Sanofi acquiring Bioverativ for $11.6B  https://t.co/O8d7SaFNig $CELG $JUNO $BIVV $SNY @danacimilluca @jonathanrockoff,en,"[{'screen_name': 'danacimilluca', 'name': 'dana cimilluca', 'id': '44470680'}, {'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}]","['http://on.wsj.com/2EZVlaf', 'http://on.wsj.com/2rshMTJ']",[],2,5,8,[],"['celg', 'juno', 'bivv', 'sny']",https://twitter.com/DanaMattioli/status/955437938283827200,False,,0,,,,,,,,[],,,,
955431027949883392,955431027949883392,2018-01-22 18:54:42 IST,2018-01-22,18:54:42,+0530,102754598,johncendpts,John Carroll,,"Celgene is keeping everything. The $JUNO ops, bb2121 and all.  $CELG  https://t.co/vA71PfFOQ6",en,[],['https://endpts.com/celgene-bags-car-t-player-juno-in-9b-buyout-as-biotech-ma-suddenly-explodes/'],[],1,6,10,[],"['juno', 'celg']",https://twitter.com/JohnCendpts/status/955431027949883392,False,,0,,,,,,,,[],,,,
955420389152354304,955420389152354304,2018-01-22 18:12:26 IST,2018-01-22,18:12:26,+0530,1407780158,drmiguelperales,Miguel Perales M.D.,,"Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer $JUNO $CELG #CARTcell   https://t.co/AzpURlTB8L",en,[],['https://www.cnbc.com/2018/01/22/celgene-to-buy-biotechnology-company-juno-therapeutics-for-about-9-billion.html'],[],0,4,9,['cartcell'],"['juno', 'celg']",https://twitter.com/DrMiguelPerales/status/955420389152354304,False,,0,,,,,,,,[],,,,
955416655009640449,955416655009640449,2018-01-22 17:57:35 IST,2018-01-22,17:57:35,+0530,174385219,mariogabelli,Mario Gabelli,,Celgene (CELG) buying JUNO @$87 cash per share,en,[],[],[],0,0,8,[],[],https://twitter.com/MarioGabelli/status/955416655009640449,False,,0,,,,,,,,[],,,,
955415740722630658,955415740722630658,2018-01-22 17:53:58 IST,2018-01-22,17:53:58,+0530,6810242,bydavidcrow,David Crow,,Celgene‚Äôs Juno deal not accretive until 2020 and then hardly at all $celg $juno #platform  https://t.co/5lfqfipbvr,en,[],[],['https://pbs.twimg.com/media/DUJRjCSXcAAWRBW.jpg'],2,8,9,['platform'],"['celg', 'juno']",https://twitter.com/bydavidcrow/status/955415740722630658,False,,1,https://pbs.twimg.com/media/DUJRjCSXcAAWRBW.jpg,,,,,,,[],,,,
955405706852798467,955405706852798467,2018-01-22 17:14:05 IST,2018-01-22,17:14:05,+0530,102754598,johncendpts,John Carroll,,Celgene bags CAR-T player Juno in $9B buyout as biotech M&amp;A suddenly explodes $CELG $JUNO  https://t.co/vA71PfFOQ6,en,[],['https://endpts.com/celgene-bags-car-t-player-juno-in-9b-buyout-as-biotech-ma-suddenly-explodes/'],[],0,30,29,[],"['celg', 'juno']",https://twitter.com/JohnCendpts/status/955405706852798467,False,,0,,,,,,,,[],,,,
955403268242444288,955403268242444288,2018-01-22 17:04:24 IST,2018-01-22,17:04:24,+0530,18294197,fiercebiotech,FierceBiotech,,"After Sanofi deal this morning, Celgene buys Juno for $9B - expects JCAR017 as bringing in $3B at peak:  https://t.co/8OqgFzzNmG $CELG $JUNO",en,[],['http://ow.ly/uK5W30hV5FZ'],[],0,15,15,[],"['celg', 'juno']",https://twitter.com/FierceBiotech/status/955403268242444288,False,,0,,,,,,,,[],,,,
955147987155587072,955147987155587072,2018-01-22 00:10:00 IST,2018-01-22,00:10:00,+0530,274233761,bradloncar,Brad Loncar,,Biotech earnings season is back. What is Celgene going to say on Thursday?   M: $RMD T: $JNJ W: $ABT $NVS T: $BIIB $CELG F: $ABBV  The entire schedule:  https://t.co/bW3wImVkzz  https://t.co/utkJDehcNe,en,[],['http://www.loncarblog.com/january-22-earnings'],['https://pbs.twimg.com/media/DUBay2KXkAI5QwR.jpg'],1,2,9,[],"['rmd', 'jnj', 'abt', 'nvs', 'biib', 'celg', 'abbv']",https://twitter.com/bradloncar/status/955147987155587072,False,,1,https://pbs.twimg.com/media/DUBay2KXkAI5QwR.jpg,,,,,,,[],,,,
954375350477361154,954375350477361154,2018-01-19 20:59:49 IST,2018-01-19,20:59:49,+0530,102754598,johncendpts,John Carroll,,#2 Is Juno worth a $10B-$12B buyout price? Analysts see megabucks deal in the making on reported Celgene talks $JUNO $CELG  https://t.co/8l2gtL5ezR,en,[],['https://endpts.com/wsj-juno-shares-rocket-higher-on-word-that-celgene-is-hunting-a-buyout-deal/'],[],0,1,5,[],"['juno', 'celg']",https://twitter.com/JohnCendpts/status/954375350477361154,False,,0,,,,,,,,[],,,,
953732259416367104,953732259416367104,2018-01-18 02:24:24 IST,2018-01-18,02:24:24,+0530,102754598,johncendpts,John Carroll,,#1 - Is Juno worth a $10B-$12B buyout price? Analysts see megabucks deal in the making on reported Celgene talks $JUNO $CELG $BLIUE  https://t.co/8l2gtL5ezR,en,[],['https://endpts.com/wsj-juno-shares-rocket-higher-on-word-that-celgene-is-hunting-a-buyout-deal/'],[],2,6,14,[],"['juno', 'celg', 'bliue']",https://twitter.com/JohnCendpts/status/953732259416367104,False,,0,,,,,,,,[],,,,
953700543695814663,953700543695814663,2018-01-18 00:18:23 IST,2018-01-18,00:18:23,+0530,19717430,zbiotech,zach,,"Celgene acquisition of Juno 'doable' but questionable, says Cantor $CELG $JUNO",en,[],[],[],0,2,5,[],"['celg', 'juno']",https://twitter.com/zbiotech/status/953700543695814663,False,,0,,,,,,,,[],,,,
953625005589397504,953625005589397504,2018-01-17 19:18:13 IST,2018-01-17,19:18:13,+0530,102754598,johncendpts,John Carroll,,Is Juno worth a $10B-$12B buyout price? Analysts see megabucks deal in the making on reported Celgene talks $JUNO $CELG $BLUE  https://t.co/8l2gtL5ezR,en,[],['https://endpts.com/wsj-juno-shares-rocket-higher-on-word-that-celgene-is-hunting-a-buyout-deal/'],[],0,7,8,[],"['juno', 'celg', 'blue']",https://twitter.com/JohnCendpts/status/953625005589397504,False,,0,,,,,,,,[],,,,
953603588256862208,953603588256862208,2018-01-17 17:53:07 IST,2018-01-17,17:53:07,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"MS $CELG Celgene could elect to return $BLUE BCMA CAR-T if it acquired $Juno. If Bluebird were to regain 100% rights to its BCMA CAR-T, the market could initially be concerned about the largest myeloma player returning a product it has touted as a key asset and drive $BLUE down.",en,[],[],[],4,3,7,[],"['celg', 'blue', 'juno', 'blue']",https://twitter.com/_B_I_O_T_E_C_H_/status/953603588256862208,False,,0,,,,,,,,[],,,,
953587999614304256,953587999614304256,2018-01-17 16:51:10 IST,2018-01-17,16:51:10,+0530,102754598,johncendpts,John Carroll,,From the night bureau: Juno shares rocket higher on word that Celgene is hunting a buyout deal $JUNO $CELG  https://t.co/8l2gtL5ezR,en,[],['https://endpts.com/wsj-juno-shares-rocket-higher-on-word-that-celgene-is-hunting-a-buyout-deal/'],[],1,4,7,[],"['juno', 'celg']",https://twitter.com/JohnCendpts/status/953587999614304256,False,,0,,,,,,,,[],,,,
953550641699475456,953550641699475456,2018-01-17 14:22:43 IST,2018-01-17,14:22:43,+0530,18294197,fiercebiotech,FierceBiotech,,"Jefferies said in a note to clients last night that a deal would ""naturally be a smart move by Celgene as the buyout would enable it to integrate Juno‚Äôs entire cell therapy platform and bring it all in house."" It sees $9.5B at top end   https://t.co/zMG9ZVY1Pi $CELG $JUNO",en,[],['http://ow.ly/9kCq30hPo22'],[],0,9,9,[],"['celg', 'juno']",https://twitter.com/FierceBiotech/status/953550641699475456,False,,0,,,,,,,,[],,,,
953509217025118208,953509217025118208,2018-01-17 11:38:07 IST,2018-01-17,11:38:07,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,^RaymondJames: $CELG Celgene to Acquire Juno $JUNO ? Gentle Investors‚Ä¶Start Your Valuation Speculating (cont)  https://t.co/BLXJUdf8pc,en,[],['http://tl.gd/n_1sqdcbl'],[],0,3,6,[],"['celg', 'juno']",https://twitter.com/_B_I_O_T_E_C_H_/status/953509217025118208,False,,0,,,,,,,,[],,,,
953388197605793792,953388197605793792,2018-01-17 03:37:14 IST,2018-01-17,03:37:14,+0530,23892927,danamattioli,Dana Mattioli,,Juno is trading up 43% after hours on WSJ Scoop that Celgene is in talks to buy the biotech company. Story:  https://t.co/YVQRpW2r2i $CELG $JUNO,en,[],['http://on.wsj.com/2EMlysO'],[],0,10,10,[],"['celg', 'juno']",https://twitter.com/DanaMattioli/status/953388197605793792,False,,0,,,,,,,,[],,,,
953382420312739840,953382420312739840,2018-01-17 03:14:16 IST,2018-01-17,03:14:16,+0530,23892927,danamattioli,Dana Mattioli,,Back-to-back deals? Celgene is in talks to buy Juno Therapeutics. Scoop  with @jonathanrockoff &amp; @danacimilluca coming to WSJ $CELG $JUNO,en,"[{'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}, {'screen_name': 'danacimilluca', 'name': 'dana cimilluca', 'id': '44470680'}]",[],[],2,24,27,[],"['celg', 'juno']",https://twitter.com/DanaMattioli/status/953382420312739840,False,,0,,,,,,,,[],,,,
953381815124938752,953381815124938752,2018-01-17 03:11:52 IST,2018-01-17,03:11:52,+0530,19717430,zbiotech,zach,,*DJ Celgene Is in Talks to Buy Juno Therapeutics -- Sources $CELG $JUNO,en,[],[],[],2,36,42,[],"['celg', 'juno']",https://twitter.com/zbiotech/status/953381815124938752,False,,0,,,,,,,,[],,,,
953213616160985088,953213616160985088,2018-01-16 16:03:30 IST,2018-01-16,16:03:30,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Dear @Celgene  Dear @Pfizer  This is the link to $SGMO ‚Äòs zinc finger protein technology page on their site. Why don‚Äôt you consider merging $PFE &amp; $CELG and buyout $SGMO ? Can you imagine the pipeline &amp; synergies this could bring about! Regards from üá≤üáπ   https://t.co/dzifvumcEe,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}]",['https://www.sangamo.com/technology/gene-regulation'],[],2,2,7,[],"['sgmo', 'pfe', 'celg', 'sgmo']",https://twitter.com/Biotech2050/status/953213616160985088,False,,0,,,,,,,,[],,,,
953205631242076160,953193602355777537,2018-01-16 15:31:46 IST,2018-01-16,15:31:46,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@_B_I_O_T_E_C_H_ @Celgene @pfizer Never thought that $SGMO could be of interest to @Celgene but now it seems to be a must partner (as a minimum) for $CELG ‚Äòs next generation of Revlimid.....,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],[],1,3,6,[],"['sgmo', 'celg']",https://twitter.com/Biotech2050/status/953205631242076160,False,,0,,,,,,,,"[{'screen_name': '_B_I_O_T_E_C_H_', 'name': 'üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑', 'id': '4859660471'}, {'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'pfizer', 'name': 'Pfizer Inc.', 'id': '56488059'}]",,,,
953180374099808256,953180374099808256,2018-01-16 13:51:25 IST,2018-01-16,13:51:25,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,uuhhmmmm  $CELG Celgene Cancer Center Consortium ‚Äì Special Request for Proposals Focused on #Zinc #Finger #Proteins in Cancer       https://t.co/unONJy3s5Z,en,[],['http://cancer.columbia.edu/events/2018-02-15-220000/celgene-cancer-center-consortium-special-request-proposals-focused-zinc'],[],3,5,6,"['zinc', 'finger', 'proteins']",['celg'],https://twitter.com/_B_I_O_T_E_C_H_/status/953180374099808256,False,,0,,,,,,,,[],,,,
950869674572505093,950869674572505093,2018-01-10 04:49:31 IST,2018-01-10,04:49:31,+0530,102754598,johncendpts,John Carroll,,"#3    After bumpy 2017, Celgene CEO says taking risk is the only way forward $CELG @BrittanyMeiling  https://t.co/ElHsBWxndb",en,"[{'screen_name': 'brittanymeiling', 'name': 'brittany meiling', 'id': '2701355767'}]",['https://endpts.com/after-bumpy-2017-celgene-ceo-says-taking-risk-is-the-only-way-forward/'],[],0,5,7,[],['celg'],https://twitter.com/JohnCendpts/status/950869674572505093,False,,0,,,,,,,,[],,,,
950395118279798784,950395118279798784,2018-01-08 21:23:48 IST,2018-01-08,21:23:48,+0530,44438256,matthewherper,Matthew Herper,,Celgene's $7 Billion Purchase Is Great For Drug Inventors. Is It Great For $CELG?  #JPM18  https://t.co/ZqhwMty9O2,en,[],['https://www.forbes.com/sites/matthewherper/2018/01/08/celgenes-7-billion-purchase-is-great-for-drug-inventors-is-it-great-for-celgene/#6b782a2f187c'],[],1,2,8,['jpm18'],['celg'],https://twitter.com/matthewherper/status/950395118279798784,False,,0,,,,,,,,[],,,,
950143431883546624,950143431883546624,2018-01-08 04:43:41 IST,2018-01-08,04:43:41,+0530,71372467,sciencescanner,David Grainger,,Big congratulations due to @MedicxiKevin @J_S_Edwards as Celgene acquire @Medicxi portfolio co Impact for $7B:  https://t.co/jFfATxfaDu $CELG,en,"[{'screen_name': 'medicxikevin', 'name': 'kevin johnson', 'id': '388309688'}, {'screen_name': 'j_s_edwards', 'name': 'jon edwards', 'id': '935854698'}, {'screen_name': 'medicxi', 'name': 'medicxi', 'id': '4828395018'}]",['http://ir.celgene.com/releasedetail.cfm?ReleaseID=1053509'],[],10,15,48,[],['celg'],https://twitter.com/sciencescanner/status/950143431883546624,False,,0,,,,,,,,[],,,,
948947448952770560,948947448952770560,2018-01-04 21:31:17 IST,2018-01-04,21:31:17,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,"#JPM18 presentations for $CELG holders $CELG 01/08 at 07:30 AM PT $AGIO 01/08 at 09:30 AM PT $XLRN 01/08 at 02:30 PM PT $BLUE 01/09 at 07:30 AM PT $JUNO 01/09 at 04:00 PM PT As a reminder, CELGENE is trading at 10-11X 2018 EPS and 9X 2019 so market values pipeline at ZERO.",en,[],[],[],0,5,7,['jpm18'],"['celg', 'celg', 'agio', 'xlrn', 'blue', 'juno']",https://twitter.com/Biotech2050/status/948947448952770560,False,,0,,,,,,,,[],,,,
944198607196033024,944198607196033024,2017-12-22 19:01:04 IST,2017-12-22,19:01:04,+0530,102754598,johncendpts,John Carroll,,Celgene shares sink after another PhIII lymphoma flop and J&amp;J steps up for the late-stage BCMA race $CELG $BLUE $JNJ  https://t.co/ZyHfUwPt63,en,[],['https://endpts.com/celgene-shares-sink-after-another-phiii-lymphoma-flop-and-jj-steps-up-for-the-late-stage-bcma-race/'],[],1,7,5,[],"['celg', 'blue', 'jnj']",https://twitter.com/JohnCendpts/status/944198607196033024,False,,0,,,,,,,,[],,,,
939880121976213504,939880121976213504,2017-12-10 21:00:57 IST,2017-12-10,21:00:57,+0530,102754598,johncendpts,John Carroll,,#ASH17: The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlight $BLUE $CELG  https://t.co/G4pjqsRy6W,en,[],['https://endpts.com/ash17-the-bcma-targeted-car-t-bb2121-from-bluebird-and-celgene-takes-a-star-turn-in-the-spotlight/'],[],2,44,41,['ash17'],"['blue', 'celg']",https://twitter.com/JohnCendpts/status/939880121976213504,False,,0,,,,,,,,[],,,,
933325648206102530,933320602747891713,2017-11-22 18:55:49 IST,2017-11-22,18:55:49,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,@Jdalexander64 Would be great if $SGMO is acquired by $CELG @Celgene expanding their pipeline arsenal ....,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],[],0,1,6,[],"['sgmo', 'celg']",https://twitter.com/Biotech2050/status/933325648206102530,False,,0,,,,,,,,[],,,,
931152993528971264,931152993528971264,2017-11-16 19:02:28 IST,2017-11-16,19:02:28,+0530,3376824064,optionsmike,Options Mike,,$CELG/ $BLUE.. Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma,en,[],[],[],0,2,9,[],"['celg', 'blue']",https://twitter.com/OptionsMike/status/931152993528971264,False,,0,,,,,,,,[],,,,
925384088453828608,925384088453828608,2017-10-31 20:58:54 IST,2017-10-31,20:58:54,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Come on @Celgene $CELG pull the trigger maybe on  $XLRN $SGMO $ZIOP $HALO $KPTI $TGTX  &amp; so many $XBI others Plus #buybacks please,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}]",[],[],1,1,5,['buybacks'],"['celg', 'xlrn', 'sgmo', 'ziop', 'halo', 'kpti', 'tgtx', 'xbi']",https://twitter.com/Biotech2050/status/925384088453828608,False,,0,,,,,,,,[],,,,
923879789584441344,923879789584441344,2017-10-27 17:21:21 IST,2017-10-27,17:21:21,+0530,102754598,johncendpts,John Carroll,,"First Celgene, now Gilead can‚Äôt accurately forecast drug sales revenue. How bad is this? $CELG $GILD  https://t.co/qu9m9yyNbj",en,[],['https://endpts.com/first-celgene-now-gilead-cant-accurately-forecast-drug-sales-revenue-whats-up-with-that/'],[],1,5,15,[],"['celg', 'gild']",https://twitter.com/JohnCendpts/status/923879789584441344,False,,0,,,,,,,,[],,,,
923654815904759808,923654815904759808,2017-10-27 02:27:23 IST,2017-10-27,02:27:23,+0530,243795494,pharmamaven,rc,,"Celgene weakness will prove to be a compelling entry point, says RBC Capital $CELG $IBB $BIIB $AMGN $BTK $XBI",en,[],[],[],1,5,16,[],"['celg', 'ibb', 'biib', 'amgn', 'btk', 'xbi']",https://twitter.com/pharmamaven/status/923654815904759808,False,,0,,,,,,,,[],,,,
923557030799007744,923557030799007744,2017-10-26 19:58:49 IST,2017-10-26,19:58:49,+0530,37718217,thedomino,Dominic Chu,,New S&amp;P 500 52-wk lows: Chipotle $CMG Molson Coors $TAP Allergan $AGN Celgene $CELG General Electric $GE Advance Auto Parts $AAP etc  @cnbc,en,"[{'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}]",[],[],1,8,10,[],"['cmg', 'tap', 'agn', 'celg', 'ge', 'aap']",https://twitter.com/TheDomino/status/923557030799007744,False,,0,,,,,,,,[],,,,
923545114810683399,923545114810683399,2017-10-26 19:11:28 IST,2017-10-26,19:11:28,+0530,20449296,barronsonline,Barron's,,"Morning Movers: Celgene Slumps, American Airlines Flies, Twitter Soars  https://t.co/QAmwJ3RdUY $CELG $AAL $TWTR $NOK $MCK $F $CSX $CHTR",en,[],['http://on.barrons.com/2lipvR8'],[],0,2,4,[],"['celg', 'aal', 'twtr', 'nok', 'mck', 'f', 'csx', 'chtr']",https://twitter.com/barronsonline/status/923545114810683399,False,,0,,,,,,,,[],,,,
915204957674049537,915204957674049537,2017-10-03 18:50:40 IST,2017-10-03,18:50:40,+0530,18294197,fiercebiotech,FierceBiotech,,"Celgene pens pact to join Bristol-Myers, Pfizer in R&amp;D race:  https://t.co/Mtccu6ZYQJ $CELG $BMY $PFE",en,[],['http://ow.ly/dP4m30fBxRy'],[],0,8,7,[],"['celg', 'bmy', 'pfe']",https://twitter.com/FierceBiotech/status/915204957674049537,False,,0,,,,,,,,[],,,,
915177120988573696,915177120988573696,2017-10-03 17:00:03 IST,2017-10-03,17:00:03,+0530,102754598,johncendpts,John Carroll,,Celgene joins the heavyweight partner club collaborating with Nimbus $CELG  https://t.co/lFVvZdGf5U,en,[],['https://endpts.com/celgene-joins-the-heavyweight-partner-club-collaborating-with-nimbus/'],[],0,15,14,[],['celg'],https://twitter.com/JohnCendpts/status/915177120988573696,False,,0,,,,,,,,[],,,,
910866199868792833,910866199868792833,2017-09-21 19:29:59 IST,2017-09-21,19:29:59,+0530,18294197,fiercebiotech,FierceBiotech,,Celgene-backed FLX picks CCR4 antagonist for clinical trials:  https://t.co/osRZjzjNEB $CELG,en,[],['http://ow.ly/Vlb930fkc3F'],[],0,11,8,[],['celg'],https://twitter.com/FierceBiotech/status/910866199868792833,False,,0,,,,,,,,[],,,,
905797873194991616,905797873194991616,2017-09-07 19:50:16 IST,2017-09-07,19:50:16,+0530,37718217,thedomino,Dominic Chu,,"14 S&amp;P 500 RECORD highs in early trade, incl: Estee Lauder $EL $CBOE Holdings Celgene $CELG Accenture $ACN Salesforce $CRM $EBAY etc  @cnbc",en,"[{'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}]",[],[],2,4,7,[],"['el', 'cboe', 'celg', 'acn', 'crm', 'ebay']",https://twitter.com/TheDomino/status/905797873194991616,False,,0,,,,,,,,[],,,,
905784428412243970,905784428412243970,2017-09-07 18:56:51 IST,2017-09-07,18:56:51,+0530,18639734,nasdaq,Nasdaq,,.@Celgene rings the @Nasdaq Opening Bell in celebration of their 30 year listing anniversary! üõéüéäüéÇ$CELG #NasdaqListed  https://t.co/0SWGszBELY,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'nasdaq', 'name': 'nasdaq', 'id': '18639734'}]",[],"['https://pbs.twimg.com/media/DJH-IQPUMAAnIov.jpg', 'https://pbs.twimg.com/media/DJH-IQmV4AEfGHm.jpg', 'https://pbs.twimg.com/media/DJH-IQ3UIAAxe6j.jpg', 'https://pbs.twimg.com/media/DJH-IQMVoAEbBMg.jpg']",0,8,14,['nasdaqlisted'],[],https://twitter.com/Nasdaq/status/905784428412243970,False,,1,https://pbs.twimg.com/media/DJH-IQPUMAAnIov.jpg,,,,,,,[],,,,
902533388380372993,902533388380372993,2017-08-29 19:38:22 IST,2017-08-29,19:38:22,+0530,102754598,johncendpts,John Carroll,,"Celgene antes up $195M more to stay close to Forma, adding neurodegeneration focus $CELG  https://t.co/zeVWFdYDFq",en,[],['https://endpts.com/celgene-antes-up-195m-more-to-stay-close-to-forma-adding-neurodegeneration-focus/'],[],0,7,10,[],['celg'],https://twitter.com/JohnCendpts/status/902533388380372993,False,,0,,,,,,,,[],,,,
902524680220880897,902524680220880897,2017-08-29 19:03:46 IST,2017-08-29,19:03:46,+0530,102754598,johncendpts,John Carroll,,"Celgene, Google double down on Armo‚Äôs PhIII immuno-oncology drug with $67M round $CELG  https://t.co/I42hn9drEP",en,[],['https://endpts.com/celgene-google-double-down-on-armos-phiii-immuno-oncology-drug-with-67m-round/'],[],5,8,11,[],['celg'],https://twitter.com/JohnCendpts/status/902524680220880897,False,,0,,,,,,,,[],,,,
892407187150123011,892407187150123011,2017-08-01 21:00:28 IST,2017-08-01,21:00:28,+0530,102754598,johncendpts,John Carroll,,"Celgene, Agios win a landmark FDA OK for new AML drug Idhifa $CELG $AGIO  https://t.co/rWClmVQn6c",en,[],['https://endpts.com/celgene-agios-win-a-landmark-fda-ok-for-new-aml-drug-idhifa/'],[],4,25,29,[],"['celg', 'agio']",https://twitter.com/JohnCendpts/status/892407187150123011,False,,0,,,,,,,,[],,,,
892404185316155394,892404185316155394,2017-08-01 20:48:32 IST,2017-08-01,20:48:32,+0530,15563814,loftus,Peter Loftus,,"Agios-developed drug licensed to Celgene, for one of the toughest cancers around... $AGIO $CELG  https://t.co/rxyQWX3Vy9",en,[],['https://twitter.com/FDAMedia/status/892403752044552192'],[],1,4,6,[],"['agio', 'celg']",https://twitter.com/Loftus/status/892404185316155394,False,https://twitter.com/FDAMedia/status/892403752044552192,0,,,,,,,,[],,,,
890910798704455681,890910798704455681,2017-07-28 17:54:21 IST,2017-07-28,17:54:21,+0530,2579225425,ritholtzwealth,Ritholtz Wealth,,"Today in market history, 1987:  Celgene IPOs under ticker $CELG. Over the last 30 years, the stock has returned 27,900% or 20.6% annually!",en,[],[],[],0,8,14,[],['celg'],https://twitter.com/RitholtzWealth/status/890910798704455681,False,,0,,,,,,,,[],,,,
889975436721172484,889975436721172484,2017-07-26 03:57:33 IST,2017-07-26,03:57:33,+0530,15563814,loftus,Peter Loftus,,Celgene pays $280M to settle lawsuit over alleged improper promotion of cancer drugs $CELG  https://t.co/3xAuQze244 via @WSJ,en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['https://www.wsj.com/articles/celgene-settles-lawsuit-over-improper-promotion-of-cancer-drugs-1501021308'],[],1,15,8,[],['celg'],https://twitter.com/Loftus/status/889975436721172484,False,,0,,,,,,,,[],,,,
889972548846465024,889972548846465024,2017-07-26 03:46:05 IST,2017-07-26,03:46:05,+0530,13171622,pharmalot,pharmalot,,Celgene will pay $280M for off-label marketing of two drugs.. Revlimid sales can pay that in 2 weeks..  https://t.co/hj3BOQvGMC #pharma $CELG,en,[],['https://www.statnews.com/pharmalot/2017/07/25/celgene-illegal-marketing-cancer-drugs/'],[],0,14,10,['pharma'],['celg'],https://twitter.com/pharmalot/status/889972548846465024,False,,0,,,,,,,,[],,,,
889918725843030017,889918725843030017,2017-07-26 00:12:12 IST,2017-07-26,00:12:12,+0530,19717430,zbiotech,zach,,*CELGENE AGREES TO PAY $280M TO RESOLVE 'WHISTLEBLOWER' SUIT $CELG,en,[],[],[],0,6,7,[],['celg'],https://twitter.com/zbiotech/status/889918725843030017,False,,0,,,,,,,,[],,,,
889124924509622273,889124924509622273,2017-07-23 19:37:55 IST,2017-07-23,19:37:55,+0530,61342056,optionshawk,Joe Kunkle,,$CELG $TSRO $CLVS - Interesting note from CSFB on 7-10 on Celgene potential for M&amp;A into PARP inhibitor  https://t.co/waWEkCFztG,en,[],[],['https://pbs.twimg.com/media/DFbOZxhXUAAXKhq.jpg'],3,7,16,[],"['celg', 'tsro', 'clvs']",https://twitter.com/OptionsHawk/status/889124924509622273,False,,1,https://pbs.twimg.com/media/DFbOZxhXUAAXKhq.jpg,,,,,,,[],,,,
888054220095537157,888054220095537157,2017-07-20 20:43:19 IST,2017-07-20,20:43:19,+0530,31546412,tradehawk,TradeHawk,,$JUNO $CELG Juno Therapeutics/Celgene drug JCAR017 gets EU Orphan desig for treatment of diffuse lrg B-cell lymphoma  https://t.co/kQz841AJyd,en,[],['http://ec.europa.eu/health/documents/community-register/html/o1890.htm'],[],0,3,7,[],"['juno', 'celg']",https://twitter.com/TradeHawk/status/888054220095537157,False,,0,,,,,,,,[],,,,
877932012585205760,877932012585205760,2017-06-22 22:21:17 IST,2017-06-22,22:21:17,+0530,61342056,optionshawk,Joe Kunkle,,"Celgene $CELG with 400 June 2018 $125 puts sold to open at $8.30 today, generally see those type into weakness...but massive breakout",en,[],[],[],1,1,11,[],['celg'],https://twitter.com/OptionsHawk/status/877932012585205760,False,,0,,,,,,,,[],,,,
875342293540241408,875342293540241408,2017-06-15 18:50:40 IST,2017-06-15,18:50:40,+0530,13171622,pharmalot,pharmalot,,Cancer patient sues Celgene for thwarting generic versions of its pricey meds..  https://t.co/LuefVkXk0N #pharma $CELG #antitrust #generic,en,[],['https://www.statnews.com/pharmalot/2017/06/15/generic/'],[],1,6,5,"['pharma', 'antitrust', 'generic']",['celg'],https://twitter.com/pharmalot/status/875342293540241408,False,,0,,,,,,,,[],,,,
871694043612360705,871692123602649088,2017-06-05 17:13:49 IST,2017-06-05,17:13:49,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"@matthewherper Dude, $BLUE has US data and $CELG as a PARTNER in multiple myeloma. Yo know, Celgene? Nanjing is irrelevant.",en,[],[],[],3,3,14,[],"['blue', 'celg']",https://twitter.com/adamfeuerstein/status/871694043612360705,False,,0,,,,,,,,"[{'screen_name': 'matthewherper', 'name': 'Matthew Herper', 'id': '44438256'}]",,,,
871692704119476229,871692704119476229,2017-06-05 17:08:30 IST,2017-06-05,17:08:30,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free ‚Äî&gt;  https://t.co/GxpmgBEPHR  $BLUE $CELG #ASCO17",en,[],['https://www.thestreet.com/story/14162047/1/bluebird-celgene-car-t-keeps-multiple-myeloma-patients-relapse-free.html'],[],1,38,47,['asco17'],"['blue', 'celg']",https://twitter.com/adamfeuerstein/status/871692704119476229,False,,0,,,,,,,,[],,,,
870286712005689345,870286712005689345,2017-06-01 20:01:35 IST,2017-06-01,20:01:35,+0530,61342056,optionshawk,Joe Kunkle,,"Celgene $CELG buyers of 3,000 June $117 calls $1.29 offer ahead of ASCO",en,[],[],[],2,5,15,[],['celg'],https://twitter.com/OptionsHawk/status/870286712005689345,False,,0,,,,,,,,[],,,,
866623471438221313,866623471438221313,2017-05-22 17:25:11 IST,2017-05-22,17:25:11,+0530,102754598,johncendpts,John Carroll,,Celgene scores another big win for megablockbuster contender ozanimod in head-to-head PhIII MS study #CELG   https://t.co/4K7cpyRIhz,en,[],['https://endpts.com/celgene-scores-another-big-win-for-megablockbuster-contender-ozanimod-in-head-to-head-phiii-ms-study/'],[],1,10,15,['celg'],[],https://twitter.com/JohnCendpts/status/866623471438221313,False,,0,,,,,,,,[],,,,
841260268642545668,841260268642545668,2017-03-13 17:40:52 IST,2017-03-13,17:40:52,+0530,102754598,johncendpts,John Carroll,,Celgene embraces MTAP cancer deal with fast-moving collaborator Agios $CELG $AGIO  https://t.co/qg1J58StpJ,en,[],['https://endpts.com/celgene-embraces-mtap-cancer-deal-with-fast-moving-collaborator-agios/'],[],0,7,10,[],"['celg', 'agio']",https://twitter.com/JohnCendpts/status/841260268642545668,False,,0,,,,,,,,[],,,,
836925552225300480,836925552225300480,2017-03-01 18:36:15 IST,2017-03-01,18:36:15,+0530,18294197,fiercebiotech,FierceBiotech,,"Celgene, Agios gain FDA speedy review for AML med enasidenib:  https://t.co/5XzkivmnAx $CELG $AGIO",en,[],['http://ow.ly/I4yQ309tgX5'],[],0,3,9,[],"['celg', 'agio']",https://twitter.com/FierceBiotech/status/836925552225300480,False,,0,,,,,,,,[],,,,
836184118140493825,836184118140493825,2017-02-27 17:30:03 IST,2017-02-27,17:30:03,+0530,18294197,fiercebiotech,FierceBiotech,,"Pfizer, Celgene-backed upstart Arrakis hopes to mine RNA spice:  https://t.co/OgZbGJj4LW $PFE $CELG",en,[],['http://ow.ly/h6Nr309ondG'],[],0,2,6,[],"['pfe', 'celg']",https://twitter.com/FierceBiotech/status/836184118140493825,False,,0,,,,,,,,[],,,,
832578447562141697,832578447562141697,2017-02-17 18:42:25 IST,2017-02-17,18:42:25,+0530,102754598,johncendpts,John Carroll,,"In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS $CELG  https://t.co/d5zUv5Pgjv",en,[],['https://endpts.com/in-the-hunt-for-a-megablockbuster-celgene-plans-fda-filing-in-wake-of-phiii-win-for-ozanimod-in-ms/'],[],1,10,11,[],['celg'],https://twitter.com/JohnCendpts/status/832578447562141697,False,,0,,,,,,,,[],,,,
824612990347571200,824612990347571200,2017-01-26 19:10:32 IST,2017-01-26,19:10:32,+0530,102754598,johncendpts,John Carroll,,With interview: Celgene scoops up freshman autoimmune startup Delinia in $775M buyout $CELG  https://t.co/f1Mzh7h1T2,en,[],['https://endpts.com/celgene-scoops-up-freshman-autoimmune-startup-delinia-in-775m-buyout/'],[],0,9,11,[],['celg'],https://twitter.com/JohnCendpts/status/824612990347571200,False,,0,,,,,,,,[],,,,
824591131619065861,824591131619065861,2017-01-26 17:43:40 IST,2017-01-26,17:43:40,+0530,102754598,johncendpts,John Carroll,,Celgene scoops up freshman autoimmune startup Delinia in $775M buyout $CELG  https://t.co/f1Mzh7h1T2,et,[],['https://endpts.com/celgene-scoops-up-freshman-autoimmune-startup-delinia-in-775m-buyout/'],[],1,8,9,[],['celg'],https://twitter.com/JohnCendpts/status/824591131619065861,False,,0,,,,,,,,[],,,,
823567092892872706,823567092892872706,2017-01-23 21:54:30 IST,2017-01-23,21:54:30,+0530,102527566,biorunup,BioRunUp,,$BIIB 5 Reasons Celgene Should Buy Biogen - by @adamfeuerstein  https://t.co/MBUL1UMic8 $CELG,et,"[{'screen_name': 'adamfeuerstein', 'name': 'adam feuerstein', 'id': '102094857'}]",['http://realmoney.thestreet.com/articles/01/23/2017/5-reasons-celgene-should-buy-biogen'],[],0,3,6,[],"['biib', 'celg']",https://twitter.com/BioRunUp/status/823567092892872706,False,,0,,,,,,,,[],,,,
818484447242846208,818161216577159168,2017-01-09 21:17:53 IST,2017-01-09,21:17:53,+0530,93913891,hfmajortom,HFMajorTom,,"This is funny $CELG moves EPS view by 2 cts ""Celgene sees FY16 adjusted EPS $5.94, consensus $5.92"" and stock moves like it's material news",en,[],[],[],1,0,5,[],['celg'],https://twitter.com/HFMajorTom/status/818484447242846208,False,,0,,,,,,,,[],,,,
818442382702088192,818442382702088192,2017-01-09 18:30:44 IST,2017-01-09,18:30:44,+0530,102754598,johncendpts,John Carroll,,"Celgene antes up $55M, grabs option to buy the autoimmune upstart Anokion $CELG  https://t.co/1SIFpkfaL2",en,[],['https://endpts.com/celgene-antes-up-55m-grabs-option-to-buy-the-autoimmune-upstart-anokion/'],[],0,4,11,[],['celg'],https://twitter.com/JohnCendpts/status/818442382702088192,False,,0,,,,,,,,[],,,,
810630312917135360,810630312917135360,2016-12-19 05:08:22 IST,2016-12-19,05:08:22,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$CELG - #FDA Tells Celgene to Stop Airing Misleading TV Ads-   https://t.co/7m1IJ6Q07R #pharma,en,[],['http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM533292.pdf'],[],0,5,6,"['fda', 'pharma']",['celg'],https://twitter.com/BioStocks/status/810630312917135360,False,,0,,,,,,,,[],,,,
809738057582804992,809738057582804992,2016-12-16 18:02:51 IST,2016-12-16,18:02:51,+0530,18294197,fiercebiotech,FierceBiotech,,"Celgene pushes into brain diseases, with a little help from: Evotec  https://t.co/inkFFEyBuc $CELG",en,[],['http://ow.ly/YaNZ307bGh9'],[],0,1,5,[],['celg'],https://twitter.com/FierceBiotech/status/809738057582804992,False,,0,,,,,,,,[],,,,
809523676399960064,809523676399960064,2016-12-16 03:50:59 IST,2016-12-16,03:50:59,+0530,102754598,johncendpts,John Carroll,,"After some careful thinking, Celgene strikes a $295M discovery deal on neurodegeneration $CELG  https://t.co/TuX0hr6yD9",en,[],['https://endpts.com/after-some-careful-thinking-celgene-strikes-a-295m-discovery-deal-on-neurodegeneration/'],[],1,12,8,[],['celg'],https://twitter.com/JohnCendpts/status/809523676399960064,False,,0,,,,,,,,[],,,,
801040567069188096,801040567069188096,2016-11-22 18:02:08 IST,2016-11-22,18:02:08,+0530,112872946,biostocks,Bio Stocks‚Ñ¢,,$CELG Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at #ASH16   https://t.co/x3xkeUvHZ1,en,[],['http://www.businesswire.com/news/home/20161122005330/en/350-Abstracts-Evaluating-Celgene-Therapies-Presented-American'],[],1,14,12,['ash16'],['celg'],https://twitter.com/BioStocks/status/801040567069188096,False,,0,,,,,,,,[],,,,
793430910653894656,793430910653894656,2016-11-01 18:04:04 IST,2016-11-01,18:04:04,+0530,15442689,coastw,Jon Iwata,,The surprising reason IBM Watson is partnering with Celgene $IBM $CELG   https://t.co/36Phw2ga6i @IBMWatson #WatsonHealth #drugsafety,en,"[{'screen_name': 'ibmwatson', 'name': 'ibm watson', 'id': '29735775'}]",['http://for.tn/2dXuNxc?xid=for_tw_sh'],[],0,6,4,"['watsonhealth', 'drugsafety']","['ibm', 'celg']",https://twitter.com/coastw/status/793430910653894656,False,,0,,,,,,,,[],,,,
791623406466793472,791623406466793472,2016-10-27 18:21:42 IST,2016-10-27,18:21:42,+0530,19717430,zbiotech,zach,,"*TWO CELGENE PATENTS ARE INVALID, U.S. PATENT OFFICE SAYS $CELG",en,[],[],[],5,4,8,[],['celg'],https://twitter.com/zbiotech/status/791623406466793472,False,,0,,,,,,,,[],,,,
791602962111926272,791602962111926272,2016-10-27 17:00:28 IST,2016-10-27,17:00:28,+0530,59393368,livesquawk,LiveSquawk,,$CELG Celgene Q3 16 Earnings Results: -Adj EPS: $1.58 (Estimate $1.48) -Revenue: $2.98B (Estimate $2.83B),en,[],[],[],0,15,10,[],['celg'],https://twitter.com/LiveSquawk/status/791602962111926272,False,,0,,,,,,,,[],,,,
788704919587004416,788704919587004416,2016-10-19 17:04:40 IST,2016-10-19,17:04:40,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Celgene Skips the Placebo, Fails Drug Development 101 $CELG  https://t.co/MVsCmp8nIx via @TheStreet",en,"[{'screen_name': 'thestreet', 'name': 'thestreet', 'id': '15281391'}]",['https://www.thestreet.com/story/13858404/1/celgene-skips-the-placebo-fails-drug-development-101.html'],[],4,25,34,[],['celg'],https://twitter.com/adamfeuerstein/status/788704919587004416,False,,0,,,,,,,,[],,,,
787810737335009280,787810737335009280,2016-10-17 05:51:31 IST,2016-10-17,05:51:31,+0530,102754598,johncendpts,John Carroll,,"Now with actual data in hand, Celgene touts an early response for Crohn‚Äôs drug mongersen $CELG (enough?)  https://t.co/VC6j01j2HB",en,[],['http://endpts.com/now-with-actual-data-in-hand-celgene-touts-an-early-response-for-crohns-drug-mongersen/'],[],0,10,9,[],['celg'],https://twitter.com/JohnCendpts/status/787810737335009280,False,,0,,,,,,,,[],,,,
781982758826573824,781982758826573824,2016-10-01 03:53:12 IST,2016-10-01,03:53:12,+0530,102754598,johncendpts,John Carroll,,Exclusive: Celgene targets a cure for myeloma/lymphoma with $600M EngMab buyout $CELG   https://t.co/eNEHEslI5p,en,[],['http://endpts.com/breaking-celgene-bags-a-new-multiple-myeloma-program-in-engmab-deal/'],[],0,11,6,[],['celg'],https://twitter.com/JohnCendpts/status/781982758826573824,False,,0,,,,,,,,[],,,,
780776143544803328,780776143544803328,2016-09-27 19:58:33 IST,2016-09-27,19:58:33,+0530,15563814,loftus,Peter Loftus,,"Goldman ranks drug companies' reliance on pricing: Horizon, Jazz at high end; Lilly, Celgene, Gilead low end $HZNP $JAZZ $LLY $CELG $GILD  https://t.co/bYy5SNMvfv",en,[],[],['https://pbs.twimg.com/media/CtXfSUeVUAE9XCg.jpg'],2,59,64,[],"['hznp', 'jazz', 'lly', 'celg', 'gild']",https://twitter.com/Loftus/status/780776143544803328,False,,1,https://pbs.twimg.com/media/CtXfSUeVUAE9XCg.jpg,,,,,,,[],,,,
777119670369476609,777119670369476609,2016-09-17 17:49:02 IST,2016-09-17,17:49:02,+0530,102754598,johncendpts,John Carroll,,Top story Friday: An acquisitive Celgene looks ready to pop a new multiple myeloma deal $CELG $BLUE  https://t.co/5f6OyN2oHz,en,[],['http://endpts.com/analyst-celgene-looks-ready-to-pop-a-new-multiple-myeloma-deal/'],[],0,7,6,[],"['celg', 'blue']",https://twitter.com/JohnCendpts/status/777119670369476609,False,,0,,,,,,,,[],,,,
776760089835401216,776760089835401216,2016-09-16 18:00:11 IST,2016-09-16,18:00:11,+0530,102754598,johncendpts,John Carroll,,Analyst: Celgene looks ready to pop a new multiple myeloma deal -- #BCMA $CELG  https://t.co/5f6OyN2oHz,en,[],['http://endpts.com/analyst-celgene-looks-ready-to-pop-a-new-multiple-myeloma-deal/'],[],1,6,5,['bcma'],['celg'],https://twitter.com/JohnCendpts/status/776760089835401216,False,,0,,,,,,,,[],,,,
775988813562806273,775988813562806273,2016-09-14 14:55:24 IST,2016-09-14,14:55:24,+0530,18294197,fiercebiotech,FierceBiotech,,"Riding higher on Celgene filing, Agios proposes $150M offering to fund late-phase trials:  https://t.co/CWcfkoOX7H $CELG $AGIO",en,[],['http://ow.ly/wJmb304ciml'],[],0,5,5,[],"['celg', 'agio']",https://twitter.com/FierceBiotech/status/775988813562806273,False,,0,,,,,,,,[],,,,
773867251464335361,773867251464335361,2016-09-08 18:25:05 IST,2016-09-08,18:25:05,+0530,2494896473,biotech2050,Biotech2050 üíé‚úã,,Wells Fargo Price Target on $HALO $30-$34 (200%+ upside potential) $CELG $IBB $XBI $RHBBY @Celgene @Roche @pfizer @abbvie @GileadSciences,en,"[{'screen_name': 'celgene', 'name': 'jin', 'id': '1350978062125588490'}, {'screen_name': 'roche', 'name': 'roche', 'id': '20815041'}, {'screen_name': 'pfizer', 'name': 'pfizer inc.', 'id': '56488059'}, {'screen_name': 'abbvie', 'name': 'abbvie', 'id': '531892451'}, {'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}]",[],[],0,0,5,[],"['halo', 'celg', 'ibb', 'xbi', 'rhbby']",https://twitter.com/Biotech2050/status/773867251464335361,False,,0,,,,,,,,[],,,,
773572117417848832,773572117417848832,2016-09-07 22:52:19 IST,2016-09-07,22:52:19,+0530,102754598,johncendpts,John Carroll,,Followed by -- Celgene is squeezing the trigger on an early FDA filing for key Agios cancer drug $CELG $AGIO   https://t.co/lth1hDQVKO,en,[],['http://endpts.com/breaking-celgene-is-squeezing-the-trigger-on-an-early-fda-filing-for-key-agios-cancer-drug/'],[],0,4,5,[],"['celg', 'agio']",https://twitter.com/JohnCendpts/status/773572117417848832,False,,0,,,,,,,,[],,,,
756042554576080896,756042554576080896,2016-07-21 13:56:06 IST,2016-07-21,13:56:06,+0530,1109414533,eduardofaus,Eduardo Faus,,CELGENE $CELG (USA) asoma la cabeza encima de su directriz bajista  https://t.co/XPnPFSSs59,es,[],[],['https://pbs.twimg.com/media/Cn4AsI4W8AAM2QA.jpg'],2,2,5,[],['celg'],https://twitter.com/EduardoFaus/status/756042554576080896,False,,1,https://pbs.twimg.com/media/Cn4AsI4W8AAM2QA.jpg,,,,,,,[],,,,
755845302653857792,755845302653857792,2016-07-21 00:52:17 IST,2016-07-21,00:52:17,+0530,3460109487,endpts,Endpoints News,,Table: Celgene $CELG   [thx Michael Yee]  https://t.co/48veJsgQDR,en,[],[],['https://pbs.twimg.com/media/Cn1NKo5VYAAog7K.jpg'],0,1,9,[],['celg'],https://twitter.com/endpts/status/755845302653857792,False,,1,https://pbs.twimg.com/media/Cn1NKo5VYAAog7K.jpg,,,,,,,[],,,,
755411449871212544,755411449871212544,2016-07-19 20:08:19 IST,2016-07-19,20:08:19,+0530,102754598,johncendpts,John Carroll,,Trending: Celgene signs Jounce as its new biotech star in $2.6B ‚Äòimmuno-oncology 2.0‚Äô pact $CELG  https://t.co/OrA4ZnOdhJ,en,[],['http://endpts.com/celgene-signs-jounce-as-its-new-biotech-star-in-2-6b-immuno-oncology-2-0-pact/'],[],0,3,5,[],['celg'],https://twitter.com/JohnCendpts/status/755411449871212544,False,,0,,,,,,,,[],,,,
755356683958939648,755356683958939648,2016-07-19 16:30:41 IST,2016-07-19,16:30:41,+0530,102754598,johncendpts,John Carroll,,Celgene signs Jounce as its new biotech star in $2.6B ‚Äòimmuno-oncology 2.0‚Äô pact -- $CELG  https://t.co/OrA4ZnOdhJ,en,[],['http://endpts.com/celgene-signs-jounce-as-its-new-biotech-star-in-2-6b-immuno-oncology-2-0-pact/'],[],2,10,8,[],['celg'],https://twitter.com/JohnCendpts/status/755356683958939648,False,,0,,,,,,,,[],,,,
743508969478586368,743508969478586368,2016-06-16 23:52:06 IST,2016-06-16,23:52:06,+0530,20449296,barronsonline,Barron's,,Celgene Is ‚ÄòBest Large-Cap Growth Story in #Biotech‚Äô  https://t.co/exFRAtvEVL $CELG  https://t.co/z4hjgdPu6y,en,[],['http://on.barrons.com/1XXHIiU'],['https://pbs.twimg.com/media/ClF5dvkWAAAqaQ6.jpg'],0,8,6,['biotech'],['celg'],https://twitter.com/barronsonline/status/743508969478586368,False,,1,https://pbs.twimg.com/media/ClF5dvkWAAAqaQ6.jpg,,,,,,,[],,,,
734731499430379520,734731499430379520,2016-05-23 18:33:34 IST,2016-05-23,18:33:34,+0530,18294197,fiercebiotech,FierceBiotech,,"CRISPR in silico simulation upstart taps Celgene, Data Collective for cash:  https://t.co/VEj8dNHWEc $CELG",en,[],['http://ow.ly/vqx4300tZKB'],[],0,1,5,[],['celg'],https://twitter.com/FierceBiotech/status/734731499430379520,False,,0,,,,,,,,[],,,,
732935795498160128,732935795498160128,2016-05-18 19:38:05 IST,2016-05-18,19:38:05,+0530,18294197,fiercebiotech,FierceBiotech,,Celgene backs $10.6M funding round for $JNJ incubated CRISPR antiviral biotech Agenovir:  https://t.co/XSfEVzjdBZ $CELG by @PharmaceuticBen,en,"[{'screen_name': 'pharmaceuticben', 'name': 'fiercelywashyourhands', 'id': '104112634'}]",['http://ow.ly/Z41s300kn1w'],[],0,6,5,[],"['jnj', 'celg']",https://twitter.com/FierceBiotech/status/732935795498160128,False,,0,,,,,,,,[],,,,
732668812202508289,732668812202508289,2016-05-18 01:57:11 IST,2016-05-18,01:57:11,+0530,102754598,johncendpts,John Carroll,,Celgene pays $200M to kick off ambitious immuno-oncology pact with Agios (includes interview) $CELG $AGIO   https://t.co/1YwA8mr08J,en,[],['http://www.fiercebiotech.com/celgene-pays-200m-to-kick-off-ambitious-immuno-oncology-pact-agios'],[],0,22,10,[],"['celg', 'agio']",https://twitter.com/JohnCendpts/status/732668812202508289,False,,0,,,,,,,,[],,,,
732536165463527425,732536165463527425,2016-05-17 17:10:06 IST,2016-05-17,17:10:06,+0530,232743364,vconomics,Anton,,Celgene is setting up for a big move. Direction still unknown (but I'm betting ‚Üë).  https://t.co/fLcgEvcM9v $CELG  https://t.co/7tGRvlOCNz,en,[],['http://bit.ly/1qpAPYv'],['https://pbs.twimg.com/media/CioQoUCUkAEVO7b.jpg'],0,7,8,[],['celg'],https://twitter.com/Vconomics/status/732536165463527425,False,,1,https://pbs.twimg.com/media/CioQoUCUkAEVO7b.jpg,,,,,,,[],,,,
725322760487063552,725322760487063552,2016-04-27 19:26:36 IST,2016-04-27,19:26:36,+0530,102754598,johncendpts,John Carroll,,Celgene helps push the startup raise at I/O player FLX to $79M $CELG  https://t.co/2Jdw9KFDzQ,en,[],['http://www.fiercebiotech.com/celgene-helps-push-startup-raise-at-i-o-player-flx-to-79m'],[],0,4,6,[],['celg'],https://twitter.com/JohnCendpts/status/725322760487063552,False,,0,,,,,,,,[],,,,
719513022989897728,719513022989897728,2016-04-11 18:40:47 IST,2016-04-11,18:40:47,+0530,274233761,bradloncar,Brad Loncar,,$CELG and $JUNO Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates  https://t.co/cpz0gvh5pu,en,[],['http://finance.yahoo.com/news/celgene-juno-announce-celgene-exercised-130800510.html?soc_src=mediacontentstory&soc_trk=tw'],[],1,16,4,[],"['celg', 'juno']",https://twitter.com/bradloncar/status/719513022989897728,False,,0,,,,,,,,[],,,,
700348459359014912,700348459359014912,2016-02-18 21:27:39 IST,2016-02-18,21:27:39,+0530,18294197,fiercebiotech,FierceBiotech,,Celgene opts in as bluebird starts first CAR-T clinical trial.  https://t.co/6VAAQhjeo2 by @JohnCFierce $BLUE $CELG,en,"[{'screen_name': 'johncfierce', 'name': 'phyllis m. yang', 'id': '739133634532106240'}]",['http://www.fiercebiotech.com/story/celgene-opts-bluebird-starts-first-car-t-clinical-trial/2016-02-18'],[],0,6,5,[],"['blue', 'celg']",https://twitter.com/FierceBiotech/status/700348459359014912,False,,0,,,,,,,,[],,,,
697409871675846657,697409871675846657,2016-02-10 18:50:45 IST,2016-02-10,18:50:45,+0530,102754598,johncendpts,John Carroll,,"Celgene, Google ante up for Armo's next-gen IL-10/PD-1 immuno-oncology combos $CELG $GOOG  https://t.co/AcWAFxoW37",en,[],['http://www.fiercebiotech.com/story/celgene-google-ante-armos-next-gen-il-10pd-1-immuno-oncology-combos/2016-02-10'],[],0,3,9,[],"['celg', 'goog']",https://twitter.com/JohnCendpts/status/697409871675846657,False,,0,,,,,,,,[],,,,
692754718561538049,692754718561538049,2016-01-28 22:32:50 IST,2016-01-28,22:32:50,+0530,19546277,yahoofinance,Yahoo Finance,,"Stocks to watch: Under Armour shares skyrocket, $FB revenue soars, Celgene drops on earnings miss  https://t.co/8TmDpZBokt $CELG $UA",en,[],['http://yhoo.it/1Plj3PU'],[],0,13,13,[],"['fb', 'celg', 'ua']",https://twitter.com/YahooFinance/status/692754718561538049,False,,0,,,,,,,,[],,,,
689585198019706880,689585198019706880,2016-01-20 04:38:17 IST,2016-01-20,04:38:17,+0530,243795494,pharmamaven,rc,,$CELG Celgene initiated with an Outperform at Credit Suisse Target $149. $IBB,en,[],[],[],0,3,5,[],"['celg', 'ibb']",https://twitter.com/pharmamaven/status/689585198019706880,False,,0,,,,,,,,[],,,,
684891171328372736,684891171328372736,2016-01-07 05:45:54 IST,2016-01-07,05:45:54,+0530,243795494,pharmamaven,rc,,Celgene $CELG was just initiated with a Buy at SunTrust and Target $145.,en,[],[],[],0,3,9,[],['celg'],https://twitter.com/pharmamaven/status/684891171328372736,False,,0,,,,,,,,[],,,,
684002387279794177,684002387279794177,2016-01-04 18:54:11 IST,2016-01-04,18:54:11,+0530,818081647,analystwire,SIAnalystWire,,"Celgene $CELG, The Safest Name To Own in Biotech - Piper Jaffray  https://t.co/E0r7dAv0U9",en,[],['http://streetinsider.com/r/11184898'],[],0,6,8,[],['celg'],https://twitter.com/AnalystWire/status/684002387279794177,False,,0,,,,,,,,[],,,,
679458375713861634,679458375713861634,2015-12-23 05:57:55 IST,2015-12-23,05:57:55,+0530,44438256,matthewherper,Matthew Herper,,"Merry Xmas, $CELG! Celgene settles U.S. patent litigation for top seller Revlimid  https://t.co/tyYunJeUQb",en,[],['http://finance.yahoo.com/news/celgene-settles-u-patent-litigation-225517549.html?soc_src=mediacontentstory&soc_trk=tw'],[],1,2,9,[],['celg'],https://twitter.com/matthewherper/status/679458375713861634,False,,0,,,,,,,,[],,,,
679457041539153920,679457041539153920,2015-12-23 05:52:37 IST,2015-12-23,05:52:37,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,$CELG Celgene is ripping after hours on patent agreement  https://t.co/gNKyznkVOn,en,[],['http://news.investors.com/technology/122215-786592-nike-apple-micron-technology-celgene-after-hours-action.htm'],[],0,0,4,[],['celg'],https://twitter.com/OphirGottlieb/status/679457041539153920,False,,0,,,,,,,,[],,,,
679409984795369475,679409984795369475,2015-12-23 02:45:37 IST,2015-12-23,02:45:37,+0530,2274875012,insiderwire,InsiderTradingWire,,"MICHAEL CASEY D  Buys $6,650,400 Worth of $CELG Celgene Corporation - #Form4 #InsiderTrading -  https://t.co/DVRHX2zYq7",en,[],['http://www.insidertradingwire.com/michael-casey-d-buys-6650400-worth-of-celg-celgene-corporation-form4-insidertrading/'],[],1,5,7,"['form4', 'insidertrading']",['celg'],https://twitter.com/InsiderWire/status/679409984795369475,False,,0,,,,,,,,[],,,,
666317693193031681,666317693193031681,2015-11-16 23:41:32 IST,2015-11-16,23:41:32,+0530,166597717,theflynews,The Fly,,Celgene jumps 2% after defeating Kyle Bass patent challenge $CELG: Full Story  https://t.co/iBeDqdmrgi,en,[],['http://bit.ly/20XedNC'],[],2,5,7,[],['celg'],https://twitter.com/theflynews/status/666317693193031681,False,,0,,,,,,,,[],,,,
660071666744094720,660071666744094720,2015-10-30 18:02:03 IST,2015-10-30,18:02:03,+0530,2334614718,openoutcrier,Open Outcrier,,$CELG (+0.5% pre) Celgene's VIDAZA Approved By EC For New Indication In Acute Myeloid Leukaemia    https://t.co/UTHZ2fqKCI,en,[],['http://stks.co/j3Mka'],[],0,7,6,[],['celg'],https://twitter.com/OpenOutcrier/status/660071666744094720,False,,0,,,,,,,,[],,,,
649972123142721536,649972123142721536,2015-10-02 21:10:04 IST,2015-10-02,21:10:04,+0530,20449296,barronsonline,Barron's,,JPMorgan calls Celgene ‚Äútoo cheap to ignore.‚Äù  http://t.co/0nSYc7KaKN $CELG $PFE $BIIB $GILD $JUNO $JPM,de,[],['http://bit.ly/1FLvB0L'],[],2,1,5,[],"['celg', 'pfe', 'biib', 'gild', 'juno', 'jpm']",https://twitter.com/barronsonline/status/649972123142721536,False,,0,,,,,,,,[],,,,
648585703820029954,648585703820029954,2015-09-29 01:20:56 IST,2015-09-29,01:20:56,+0530,18294275,fiercepharma,FiercePharma,,"Sorry, Celgene, patent board says. Bass can challenge your IP, and profit, too  http://t.co/T8Ge1PlpsE $CELG #pharma by @CarlyHFierce",en,"[{'screen_name': 'carlyhfierce', 'name': 'carly helfand', 'id': '1379301222'}]",['http://www.fiercepharma.com/story/sorry-celgene-patent-board-says-bass-can-challenge-your-ip-and-profit-too/2015-09-28'],[],0,4,6,['pharma'],['celg'],https://twitter.com/FiercePharma/status/648585703820029954,False,,0,,,,,,,,[],,,,
